WO2007024901A1 - Cytokine modulators and related methods of use - Google Patents
Cytokine modulators and related methods of use Download PDFInfo
- Publication number
- WO2007024901A1 WO2007024901A1 PCT/US2006/032847 US2006032847W WO2007024901A1 WO 2007024901 A1 WO2007024901 A1 WO 2007024901A1 US 2006032847 W US2006032847 W US 2006032847W WO 2007024901 A1 WO2007024901 A1 WO 2007024901A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rosehips
- resveratrol
- composition
- blackberry
- blueberry
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 37
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 89
- 239000000203 mixture Substances 0.000 claims abstract description 207
- 244000078534 Vaccinium myrtillus Species 0.000 claims abstract description 126
- 239000000284 extract Substances 0.000 claims abstract description 118
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 113
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 112
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 112
- 229940016667 resveratrol Drugs 0.000 claims abstract description 112
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 97
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 96
- 235000021014 blueberries Nutrition 0.000 claims abstract description 96
- 235000017848 Rubus fruticosus Nutrition 0.000 claims abstract description 91
- 235000021029 blackberry Nutrition 0.000 claims abstract description 90
- 235000015752 Aframomum melegueta Nutrition 0.000 claims abstract description 85
- 244000227206 Aframomum melegueta Species 0.000 claims abstract description 85
- FQWLMRXWKZGLFI-DAFODLJHSA-N 5-[6-hydroxy-2-(4-hydroxyphenyl)-4-[(e)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl]benzene-1,3-diol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1C(C=1C=C(O)C=C(O)C=1)C(C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-DAFODLJHSA-N 0.000 claims abstract description 20
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 18
- 230000028709 inflammatory response Effects 0.000 claims abstract description 17
- 108010002352 Interleukin-1 Proteins 0.000 claims description 128
- 102000000589 Interleukin-1 Human genes 0.000 claims description 123
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 92
- 102100032752 C-reactive protein Human genes 0.000 claims description 91
- 230000014509 gene expression Effects 0.000 claims description 67
- 206010061218 Inflammation Diseases 0.000 claims description 60
- 230000004054 inflammatory process Effects 0.000 claims description 60
- 239000000843 powder Substances 0.000 claims description 45
- 230000015572 biosynthetic process Effects 0.000 claims description 39
- 238000003786 synthesis reaction Methods 0.000 claims description 39
- 235000015872 dietary supplement Nutrition 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims 1
- 235000018735 Sambucus canadensis Nutrition 0.000 abstract description 46
- 235000008995 european elder Nutrition 0.000 abstract description 46
- 235000007123 blue elder Nutrition 0.000 abstract description 45
- 235000007124 elderberry Nutrition 0.000 abstract description 45
- 230000004044 response Effects 0.000 abstract description 33
- 240000001717 Vaccinium macrocarpon Species 0.000 abstract description 21
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 abstract description 21
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 abstract description 21
- 235000004634 cranberry Nutrition 0.000 abstract description 21
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract description 19
- 235000013793 astaxanthin Nutrition 0.000 abstract description 19
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract description 19
- 229940022405 astaxanthin Drugs 0.000 abstract description 19
- 239000001168 astaxanthin Substances 0.000 abstract description 19
- -1 astaxanthin) Chemical compound 0.000 abstract description 17
- 229940106134 krill oil Drugs 0.000 abstract description 16
- 235000009108 Urtica dioica Nutrition 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 244000019459 Cynara cardunculus Species 0.000 abstract description 8
- 235000019106 Cynara scolymus Nutrition 0.000 abstract description 8
- 235000016520 artichoke thistle Nutrition 0.000 abstract description 8
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 8
- 240000007817 Olea europaea Species 0.000 abstract description 7
- 230000002159 abnormal effect Effects 0.000 abstract description 7
- 240000007551 Boswellia serrata Species 0.000 abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 5
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 229960005375 lutein Drugs 0.000 abstract description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract description 5
- 235000008210 xanthophylls Nutrition 0.000 abstract description 5
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract description 4
- 244000223014 Syzygium aromaticum Species 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract description 3
- 235000018062 Boswellia Nutrition 0.000 abstract description 3
- 235000012035 Boswellia serrata Nutrition 0.000 abstract description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract description 3
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 3
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 abstract description 3
- 244000178231 Rosmarinus officinalis Species 0.000 abstract description 3
- 244000151637 Sambucus canadensis Species 0.000 abstract description 3
- 235000021324 borage oil Nutrition 0.000 abstract description 3
- 235000008524 evening primrose extract Nutrition 0.000 abstract description 3
- 229940089020 evening primrose oil Drugs 0.000 abstract description 3
- 239000010475 evening primrose oil Substances 0.000 abstract description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 3
- 235000001785 ferulic acid Nutrition 0.000 abstract description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 3
- 229940114124 ferulic acid Drugs 0.000 abstract description 3
- 235000008384 feverfew Nutrition 0.000 abstract description 3
- 235000002532 grape seed extract Nutrition 0.000 abstract description 3
- 229940087603 grape seed extract Drugs 0.000 abstract description 3
- 235000020688 green tea extract Nutrition 0.000 abstract description 3
- 229940094952 green tea extract Drugs 0.000 abstract description 3
- 229960005431 ipriflavone Drugs 0.000 abstract description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 abstract description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 abstract description 2
- 229930003802 tocotrienol Natural products 0.000 abstract description 2
- 239000011731 tocotrienol Substances 0.000 abstract description 2
- 229940068778 tocotrienols Drugs 0.000 abstract description 2
- 235000019148 tocotrienols Nutrition 0.000 abstract description 2
- 244000274883 Urtica dioica Species 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 152
- 240000000851 Vaccinium corymbosum Species 0.000 description 72
- 241000208829 Sambucus Species 0.000 description 44
- 238000012360 testing method Methods 0.000 description 39
- 239000003826 tablet Substances 0.000 description 31
- 230000028327 secretion Effects 0.000 description 27
- 102000015696 Interleukins Human genes 0.000 description 24
- 108010063738 Interleukins Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 239000000902 placebo Substances 0.000 description 21
- 229940068196 placebo Drugs 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 235000021028 berry Nutrition 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 239000000090 biomarker Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 241000219422 Urtica Species 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000004968 inflammatory condition Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000019216 blueberry extract Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000018276 interleukin-1 production Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- FQWLMRXWKZGLFI-YVYUXZJTSA-N (-)-trans-epsilon-viniferin Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@@H](C=1C=C(O)C=C(O)C=1)[C@H](C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-YVYUXZJTSA-N 0.000 description 4
- 235000018811 Aframomum Nutrition 0.000 description 4
- 241001127758 Aframomum Species 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000011449 Rosa Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229940055416 blueberry extract Drugs 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000013595 supernatant sample Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 3
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000947853 Vibrionales Species 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000020237 cranberry extract Nutrition 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000897 modulatory effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 235000020748 rosemary extract Nutrition 0.000 description 3
- 229940092258 rosemary extract Drugs 0.000 description 3
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FQWLMRXWKZGLFI-UHFFFAOYSA-N cis epsilon-viniferine Natural products C1=CC(O)=CC=C1C=CC1=CC(O)=CC2=C1C(C=1C=C(O)C=C(O)C=1)C(C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-UHFFFAOYSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- SXRAUGAFMDOHKN-UHFFFAOYSA-N epsilon-viniferin Natural products CC1(Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2C1(C)c4cc(O)cc(O)c4)c5ccc(O)cc5 SXRAUGAFMDOHKN-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000010667 rosehip oil Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000239368 Euphausia Species 0.000 description 1
- 241000239370 Euphausia superba Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010000849 leukocyte esterase Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000001395 rosa canina l. seed extract Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Definitions
- the present invention relates to inflammation within the body, and more particularly, to regulating inflammation to treat conditions and diseases associated therewith.
- Inflammation has been linked to a variety of conditions and diseases that affect the body. For example, inflammation within joints is known to worsen the symptoms of and structural deformities caused by arthritis and rheumatoid diseases, such as bursitis, tendonitis, myositis and osteoarthritis, as well as bone and joint destructive diseases, such as osteoporosis.
- arthritis and rheumatoid diseases such as bursitis, tendonitis, myositis and osteoarthritis, as well as bone and joint destructive diseases, such as osteoporosis.
- Inflammation also is known to contribute to a variety of cardiovascular and metabolic disease processes, such as atherosclerosis, thrombosis, and insulin resistance associated with obesity. Atherosclerosis may increase the chances of stroke and myocardial infarction and insulin resistance may lead to diabetes. [0005] Inflammation is also thought to contribute to the development of neurological disorders, for example, Alzheimer's disease.
- cytokines which induce signaling cascades that provide an inflammatory response.
- cytokines play a role in inflammatory reaction in response to foreign and infectious agents, traumatic or chronic injury, and abnormal chemical or physical stresses.
- treatments have been developed to regulate the release of inflammatory cytokines, or the signaling of inflammatory cytokines, specifically the interleukin-1 (IL-1 ) cytokine from macrophages.
- IL-1 interleukin-1
- Patent 5,635,478 to Vignery discloses the use of calcitonin gene related peptide (CGRP) to regulate IL-1 release, and thereby treat rheumatoid arthritis.
- CGRP calcitonin gene related peptide
- the composition can comprise rosehips and at least one of blackberry, blueberry and elderberry.
- the composition can comprise rosehips, resveratrol, and at least one of blackberry, blueberry, elderberry, and cranberry.
- the composition can comprise rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, elderberry, and cranberry.
- the composition can comprise rosehips and krill oil.
- the composition can comprise rosehips, blackberry, blueberry, elderberry and krill oil.
- the composition can comprise rosehips, resveratrol and Aframomum melegueta.
- the composition can comprise rosehips, at least one of resveratrol and viniferin, and Aframomum melegueta.
- the composition can comprise rosehips, resveratrol and astaxanthin.
- the composition can comprise rosehips, Aframomum melegueta, and at least one of blackberry, blueberry, elderberry, and cranberry.
- the composition can comprise at least one ingredient chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocothenols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid.
- the composition can comprise rosehips, nettle root, olive extract and artichoke.
- the composition can comprise rosehips, resveratrol and astaxanthin.
- the invention can provide methods for modulating or controlling an immune response and/or an inflammatory condition in a subject, the method comprising administering to the subject an effective amount of the composition of the invention to modulate or control the immune response and/or the inflammatory condition.
- the composition can inhibit the function of an immunomodulatory or pro-inflammatory cell, for example, a macrophage and/or a leukocyte.
- the composition can inhibit the expression of the genes that produce interleukin cytokines, for example, by preventing the genetic transcription of those genes.
- the composition can inhibit the interleukin cytokine inflammation response mechanism.
- the composition can modulate expression of an immunomodulatory or pro-inflammatory cell, for example by preventing an increase in expression, secretion, and/or synthesis levels of an immunomodulatory or pro-inflammatory cell.
- the composition can modulate or control pro-immunomodulatory and/or pro-inflammatory responses in skeletal mass, joints, muscle, tissue, arteries, veins, capillaries, and other organs, systems and/or cells.
- the invention can provide a method of regulating and/or controlling the function of immune cells, such as macrophages, leukocytes and lymphocytes, by administering an effective amount of the composition to a subject.
- the invention can provide a method for regulating cytokine release, also referred to as secretion, from cells in a subject by administering to a subject a composition that modulates the synthesis, expression, or secretion of a mediator of inflammation.
- the invention can provide a method that inhibits the response of cells to an interleukin cytokine by administering to a subject an effective amount of the composition of the invention.
- this administration can modulate the production of inflammation biomarkers, for example, C reactive protein, which is a biomarker produced by the liver that is indicative of excessive inflammation in the body.
- the invention can provide a method for treating a disease or abnormal condition caused by inflammation by administering a therapeutically effective amount of the composition.
- the disease or abnormal condition includes at least one of a cardiovascular disease or condition, thrombosis, a metabolic condition related to insulin resistance and obesity, a traumatic injury, arthritis, osteoporosis, and Alzheimer's disease.
- the method can include administering the composition to a subject having an inflammatory condition to relieve or eliminate pain, tenderness, infection and/or discomfort following traumatic injuries, surgery or other events that may cause inflammation.
- the present invention provides a composition and related methods for treating a variety of immunomodulatory- and inflammation-based conditions, symptoms and diseases. Because the ingredients used are readily available and relatively inexpensive, the present invention provides a simple and cost-effective solution for treating a variety of inflammation-caused ailments and conditions. Furthermore, because the ingredients are relatively stable, many can be mixed with other materials and provided in a multipurpose supplement or food product. [0016]
- FIG. 1 is a sectional view of a blood vessel of a subject having atherosclerotic plaque development before being treated with the composition of the present invention in Example 3;
- Fig. 2 is a second sectional view of the blood vessel and a liver of a subject that illustrates the effects of interleukin cytokines in atherosclerotic plaque development in Example 3; and [0019] Fig. 3 is a third sectional view of the blood vessel and the liver of a subject that illustrates the effects of the composition on interleukin cytokines in atherosclerotic plaque development in Example 3.
- Figure 4 is a line graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression Levels in the Total Study Population.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 4 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
- Figure 5 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression in the Total Study Population.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 5 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 6 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression Levels in Test Subjects having a Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 6 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
- Figure 7 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression in Test Subjects Having a Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- Figure 7 The results reported in Figure 7 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 8 illustrates Baseline vs.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum metegueta
- R indicates resveratrol.
- the results reported in Figure 8 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 9 illustrates Baseline vs. 12 Weeks Normalized Ex vivo IL-1 Expression in Human Subjects Having a Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 9 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
- Figure 10 illustrates Baseline vs. 12 Weeks Normalized Ex vivo IL-I Expression in Human Subjects Have Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum metegueta
- R indicates resveratrol.
- Figure 10 The results reported in Figure 10 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 11 illustrates Baseline vs.
- Figure 11 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum metegueta
- R indicates resveratrol
- the results reported in Figure 12 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 13 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene Expression in Test Subjects having a Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 13 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
- Figure 14 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene Expression in Test Subjects having Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum metegueta
- R indicates resveratrol.
- the results reported in Figure 14 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
- Figure 15 illustrates Baseline vs. 12 Weeks Normalized 11-1 Gene Expression in Test Subjects having a non-Pattern 1 Genotype.
- RH indicates Rosehips
- B indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry
- AM indicates Aframomum melegueta
- R indicates resveratrol.
- the results reported in Figure 15 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
- a composition of the invention can include one or more ingredients chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid.
- xanthophyll e.g., astaxanthin
- green coffee extract chlorogenic acid
- ferulic acid e.g., astaxanthin
- a composition of the invention can include rosehips and at least one of blackberry, blueberry, elderberry and krill oil.
- a composition also can include rosehips, resveratrol and Aframomum melegueta.
- Another composition can include rosehips, resveratrol and astaxanthin.
- a composition of the present invention can include rosehips, Aframomum melegueta, and at least one of viniferin and resveratrol.
- a further composition of the invention can include rosehips,
- Aframomum melegueta and at least one of blueberry, blackberry, elderberry, and cranberry.
- Another composition can include rosehips, resveratrol and at least one of blueberry, blackberry, elderberry, and cranberry.
- a further composition can include rosehips, at least one of viniferin and resvertrol, and at least one of blueberry, blackberry, elderberry, and cranberry.
- the composition can be administered in any of the dosages recited herein to inhibit cytokine expression, production, reception, secretion and/or release, as well as inhibit the cytokine response, thereby reducing or eliminating an immunomodulatory and/or inflammatory response.
- exemplary cytokines such as IL-1 and/or IL-6
- Table I Acceptable dosages of the ingredients that may be effective at modulating cytokines, for example, regulating the production, reception, secretion and/or release of exemplary cytokines, such as IL-1 and/or IL-6, are presented in Table I below. Each dosage in Table I is an estimated effective daily dosage in milligrams. Furthermore, all the dosages in Table I are presented in ranges of from about the recited lower limit to about the upper limit. For example, the nettle Dosage A recites "250-2500", which represents a dosage of about 250 to about 2500 milligrams of nettle per day.
- the ingredients identified above in Table I are readily commercially available. Depending on the application and/or the supplier, the ingredient may be an extract of a specific potency, a pure ingredient, an ingredient mixed with excipients, and in a variety of physical forms, e.g., liquid or powder.
- the ingredient identified as INM-176 is a compound of unknown composition available from Scigenic Company, Ltd. of Seoul, Korea.
- the composition can include one or more than one rosehip ingredient.
- rosehip ingredients include, without limitation, dried rosehips, rosehip oil, and rosehip extracts.
- a rosehip ingredient can be obtained from any of the multiple species of plants that belong to the Rosa family, for example Rosa canina.
- rosehips can include the fruit, petals and/or seeds of the Rosa plants.
- a composition of the invention can contain one or more than one rosehips ingredient.
- a dietary supplement can contain dried rosehips as well as rosehips extract.
- a composition can contain any amount of a rosehips component.
- At least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a rosehips ingredient.
- a composition contains between about 500 mg and about 5000 mg of a rosehips ingredient and acceptably between about 500 mg and about 1500 mg.
- the composition can include one or more than one blackberry ingredient.
- blackberry ingredients include, without limitation, dried blackberry, blackberry powder, and blackberry extracts.
- a blackberry ingredient can be obtained from any of the multiple species of plants that belong to the Rubus family, for example Rubus fruticosus.
- a composition of the invention can contain one or more than one blackberry ingredient.
- a dietary supplement can contain blackberry powder as well as blackberry extract.
- a composition can contain any amount of a blackberry component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a blackberry ingredient.
- a composition contains between about 100 mg and about 1000 mg of a blackberry ingredient.
- the composition can include one or more than one blueberry ingredient.
- blueberry ingredients include, without limitation, dried blueberry, blueberry powder, and blueberry extracts.
- a blueberry ingredient can be obtained from any of the multiple species of plants that belong to the Vaccinium family, for example, Vaccinium corymbosum.
- Any method can be used to prepare a blueberry ingredient. As an example, conventional harvesting, drying and powdering methods can be used to prepare blueberry powder.
- blueberry can be obtained commercially from Van Drunen Farms Futureceuticals of Santa Rosa, California.
- a composition of the invention can contain one or more than one blueberry ingredient.
- a dietary supplement can contain blueberry powder as well as blueberry extract.
- a composition can contain any amount of a blueberry component.
- at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a blueberry ingredient.
- a composition contains between about 200 mg and about 2000 mg of a blueberry ingredient.
- the composition can include one or more than one elderberry ingredient.
- elderberry ingredients include, without limitation, elderberry extracts, dried elderberry and elderberry powder.
- An elderberry ingredient can be obtained from any of the multiple species of plants that belong to the Sambucus family, for example, Sambucus canadensis.
- Any method can be used to prepare an elderberry ingredient.
- conventional extraction techniques can be used to prepare an elderberry extract.
- elderberry can be obtained commercially from Artemis International of Fort Wayne, Indiana.
- a composition of the invention can contain one or more than one elderberry ingredient.
- a dietary supplement can contain elderberry powder as well as elderberry extract.
- a composition can contain any amount of an elderberry component.
- at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be an elderberry ingredient.
- a composition contains between about 400 mg and about 4000 mg of an elderberry ingredient.
- the composition can include Aframomum melegueta.
- Aframomum melegueta ingredients include, without limitation, pulverized Aframomum melegueta seeds, Aframomum melegueta powder, and Aframomum melegueta extracts.
- Any method can be used to prepare an Aframomum melegueta ingredient.
- conventional harvesting, drying and extracting methods can be used to prepare Aframomum melegueta extracts.
- Aframomum melegueta can be obtained commercially from Frontier Natural Products Cooperative of Norway, Iowa.
- a composition of the invention can contain one or more than one Aframomum melegueta ingredient.
- a dietary supplement can contain Aframomum melegueta powder as well as Aframomum melegueta extract.
- a composition can contain any amount of a Aframomum melegueta component.
- at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a Aframomum melegueta ingredient.
- a composition contains between about 500 mg and about 1500 mg of a Aframomum melegueta ingredient.
- a composition of the invention can include krill oil.
- Krill oil can be obtained from any member of the Euphausia family, for example Euphausia superba. Conventional oil producing techniques can be used to obtain the krill oil.
- krill oil can be obtained commercially from Neptune Technologies and Bioresources of Quebec, Canada.
- a composition can contain any amount of krill oil. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a krill oil. Typically, a composition contains between about 300 mg and about 3000 mg of a krill oil ingredient.
- the composition includes resveratrol
- the resveratrol can be obtained from an extract of grape skin or other grape components, including the grape vine. Resveratrol can be present in the composition in one or more different forms, for example, extract form and powder form. Resveratrol can be obtained commercially from Charles Bowman & Co. of Holland, Michigan.
- the composition can further include a resveratrol ingredient that comprises resveratrol and/or derivatives thereof.
- a resveratrol ingredient may be any oligomer of resveratrol, such as ⁇ -viniferin, which is a dimer of resveratrol.
- the resveratrol ingredient can include resveratrol in combination with derivatives of resveratrol.
- the resvertrol ingredient is Resveravine ® (BioSerae Laboratoires, S.A., Pare Technoconce du Lauragais, Bram, France), which contains both resveratrol and ⁇ -viniferin.
- a composition can contain any amount of a resveratrol ingredient. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a resveratrol ingredient. Typically, a composition contains between about 100 mg and about 1000 mg of a resveratrol ingredient.
- the xanthophyll can be astaxanthin.
- Astaxanthin can be obtained from natural sources or synthesized.
- astaxanthin can be obtained from algae, fungi and/or crustaceans.
- One type of astaxanthin can be obtained commercially from Cyanotech Corporation of Kailua-Kona, Hawaii.
- a composition can contain any amount of an astaxanthin ingredient. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be astaxanthin. Typically, a composition contains between about 0.5 mg and about 50 mg of an astaxanthin ingredient.
- the composition can include one or more pharmaceutically acceptable excipients, for example, croscarmellose sodium, maltodextrin, silicified microcrystalline cellulose, silicon dioxide, stearic acid, hydroxyl propyl methyl cellulose (HPMC), lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose and the like.
- pharmaceutically acceptable excipients for example, croscarmellose sodium, maltodextrin, silicified microcrystalline cellulose, silicon dioxide, stearic acid, hydroxyl propyl methyl cellulose (HPMC), lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose and the like.
- Diluents and other additives such as one or more pharmaceutically acceptable binding agents, fillers, supports, thickening agents, taste-improving agents, coloring agents, preservatives, proteins, antimicrobials, chelating agents, inert gases, stabilizers, regulators, emulsifiers or mixtures thereof, can be used depending on the form of the composition employed.
- the ingredients of the composition can be processed into forms having varying delivery systems. For example, the ingredients can be processed and included in capsules, tablets, gel tabs, lozenges, strips, granules, powders, concentrates, solutions, lotions, creams or suspensions. The ingredients can also be administered into the respiratory tract, e.g.
- the ingredients can be formulated, individually or in combination, with other foods to provide pre-measured nutritional supplements, supplemented foods, for example, single serving bars.
- the composition can include one ingredient administered in tablet form, and another ingredient administered in capsule form. More generally, the composition can be formulated for a variety of administration routes, for example, intravenously, intramuscularly, subcutaneously, nasally, sublingualis intrathecally, topically or intradermally.
- the dosages of the composition may be administered in increments determined by the disease or condition being treated.
- the composition may be administered in multiple successive dosages, spaced as frequently as about 6 to about 12 hours apart, and as long as about 2 weeks apart.
- Daily dosages may be administered for a period to obtain symptomatic relief from inflammatory tenderness, swelling and pain.
- the dosages may be adjusted to maintain the relief from these symptoms.
- Treatment may be a period of weeks or months, or optionally, indefinitely for chronic diseases or conditions.
- An exemplary composition of the invention including rosehips, blackberry powder, blueberry powder and elderberry extract can be manufactured in tablet form according to the following processes.
- Other administration mediums, such as gel tabs, capsules, liquid and sustained release formulations, etc. can be formulated and prepared according to manufacturing techniques well known in the pharmaceutical industry.
- Rosehips, blackberry powder, and blueberry powder in the amounts recited in Dosage A in Table Il above are added to silicone dioxide and placed in a polybag and blended until uniformly and homogeneously mixed.
- This resultant blend is placed in a Patterson Kelley (P. K.) 100 blender available from Patterson-Kelley Co., East Stroudsburg, Pennsylvania.
- the following ingredients in the order listed are then passed through a Sweco separator equipped with a 20-mesh screen available from Sweco, Inc. of Florence, Kentucky directly into the P. K. 100 blender: dextrose, croscarmellose sodium, and silicified microcrystalline cellulose.
- the resultant composition is blended in the P. K. 100 blender for 15 minutes.
- a vegetable-based stearic acid powder is then passed through the Sweco separator directly into the P. K. 100 blender. The resultant mixture is blended for an additional five minutes. The resulting mixture is discharged into totes or super sacks, compressed, and punched into tablets by conventional apparatus.
- An acceptable range weight for each individual tablet is from about 250 mg to about 500 mg.
- the amount of rosehips in each tablet is about 1200 mg, the amount of blackberry is about 165 mg and the amount of blueberry is about 330 mg. Tablets manufactured according to this process can be used in the in vivo testing described herein.
- a soft gel capsule of the composition can be manufactured to include krill oil. This capsule can be manufactured using conventional capsule manufacturing techniques.
- the amount of krill oil in each capsule is about 300 mg.
- These capsules can be administered alone or in conjunction with the tablets of other ingredients of the composition as part of the in vivo testing described herein.
- Other compositions of the invention including either rosehips and blackberry powder, or rosehips and blueberry powder, can be manufactured in tablet form according to the tableting process described above.
- the amount of rosehips in the rosehips/blackberry tablet is about 300 mg, and the amount of blackberry is about 80 mg.
- the amount of rosehips in the rosehips/blueberry tablet is about 300 mg, and the amount of blueberry is about 40 mg. Tablets manufactured according to this process can be used in the in vivo testing described herein as desired.
- compositions including rosehips, resveratrol and Aframomum melegueta can be manufactured in table form according to the tableting process described above, with about 300 mg rosehips, 10 mg resveratrol and 75 mg Aframomum melegueta extract.
- composition of the invention including rosehips, resveratrol and astaxanthin can be manufactured in table form according to the tableting process described above, with about 300 mg rosehips, 10 mg resveratrol and 1 mg astaxanthin.
- composition of the invention including olive extract, artichoke, nettle root and rosehips can be manufactured in tablet form according to the following process.
- Olive extract, artichoke, nettle root and rosehips in the amounts recited in Dosage A in Table Il above are added to silicone dioxide and placed in a polybag and blended until uniformly and homogeneously mixed.
- This resultant blend is placed in a Patterson Kelley (P. K.) 100 blender available from Patterson-Kelley Co., East Stroudsburg, Pennsylvania.
- the following ingredients in the order listed are then passed through a Sweco separator equipped with a 20-mesh screen available from Sweco, Inc. of Florence, Kentucky, directly into the P. K.
- the present invention can include an ingredient screening process for selecting ingredients that are optimal for particular health conditions, and that can be used in the composition as desired.
- the active ingredients can be selected via a unique screening process.
- the various factors include biological, commercial, regulatory, and descriptive discriminators. Some preferred discriminators and their weighted values are outlined Table 2. Preferably, the discriminators are assigned a weight based upon business or consumer driven objectives.
- a weight of 3 means that the discriminator carries heavy weighting or importance in the selection process ("Factor 3 Discriminator”); 2 means that the discriminator carries significant weight, but less than a weight factor of 3 in the selection process (“Factor 2 Discriminator”); and 1 carries the least weight as a discriminator (“Factor 1 Discriminator”).
- Fractional bioavailability is the percentage of the active compounds in an orally ingested ingredient (expressed as a fraction) that is absorbed into the body, and is generally available to body tissues via the circulation. For example, a fractional availability of 0.10 indicates that 10% of an orally ingested ingredient's actives are absorbed from the intestinal tract and are (for some period of time) transported in the circulation.
- the primary objective is to find an effective and commercially successful IL-1 modulator for human use. Selection of the best candidates is accomplished by summing the discriminator weights for each candidate and comparing total weighted score.
- performance of an active ingredient in modulating IL-1 is relevant, as is the expense to obtain the particular ingredient and the availability of the ingredient.
- Other factors relevant to commercial success are the ingredient's toxicity and safety as well as the technical and regulatory acceptance of the ingredient in the market where the composition will be sold.
- Factor 3 Discriminators are assigned weights and Factor 2 and Factor 1 Discriminators are also considered in the selection process.
- the therapeutic composition or ingredient is preferably subjected to an ex vivo clinical evaluation to confirm the biological properties and effects.
- the subject consumes the therapeutic composition or ingredient.
- Serial blood samples are obtained from the subject before and following consumption over a time period when the ingredient's active components are likely to be absorbed by and transported within the circulatory system of the body, which is about 6 hours for most chemicals.
- These blood samples are added to an in vitro bioassay system which has an assay or test readout that is sensitive to changes in the physiology of the system of interest.
- the results of this test referred to as an ex vivo test, are compared to the results from the in vitro clinical. The closer the results of the in vitro and ex vivo evaluations the greater the likelihood that the therapeutic will have desired effect within the body.
- the ingredients of the composition can modulate cytokines via at least two different biological mechanisms.
- the ingredients can inhibit the production, i.e., synthesis, of interleukin cytokines.
- the ingredients prevent the mRNA transcription of the genes that code for the production of the interleukin cytokines. Therefore, with genetic transcription blocked, the cytokines can not be synthesized by or in the body.
- the ingredients can inhibit the cascading response of chemicals and cells in the body to the interleukin cytokines. More particularly, the ingredients can prevent the production of-among other compounds-acute phase proteins, for example, C reactive protein (CRP).
- CRP C reactive protein
- CRP is synthesized in the human liver by hepatocytes in response to interleukin cytokines, e.g., IL-1 and IL-6, under traumatic and/or inflammatory conditions.
- the ingredients can affect the response mechanism of cells, for example, liver cells, to interleukin cytokines so that those cells reduce or stop production of CRP.
- human white blood cells specifically THP- 1 cells obtained from ATCC of Manassas, Virginia, were grown under conditions recommended by ATCC in a humidified 37 0 C incubator, which was supplied with 5% carbon dioxide.
- THP- 1 cells were plated in 96 well plates. Specifically, 5 X 10 5 THP- 1 cells were plated in RPMI 1640 supplement with 10% fetal bovine serum and antibiotics, such as penicillin and streptomycin. With these cell samples plated, they were then dosed.
- each of the ingredients was administered to the plated THP-1 cells in varying doses, specifically, 100 ug/ml, 10 ug/ml, 1 ug/ml and 0 ug/ml.
- 100 ug/ml, 10 ug/ml, 1 ug/ml and 0 ug/ml 100 micrograms per milliliter of nettle root extract were administered, in another, 10 micrograms per milliliter were administered, in another 1 microgram per milliliter were administered, and in yet another no nettle root was administered.
- the THP-1 cells, now dosed with the desired ingredients were returned to the incubator and incubated for 4 hours under the same conditions.
- LPS lipopolysaccharide
- the LPS treated cultures were returned to the incubator for an additional 16 hours.
- the cultures were then centrifuged at 1000 Gs for about 5 minutes to obtain a supernatant.
- the supernatants were then labeled and organized for IL-1 detection.
- each supernatant was tested for presence of IL-1 according to a conventional IL-1 testing protocol provided by the supplier of the tests, Biosource International of Camarillo, California. The specific protocol is provided in the reference, Protocol Booklet, Human IL-1 , (2001 ), available from Biosource International, which is hereby incorporated by reference.
- the plate was washed again as before and 100 microliters of substrate solution, (TMB), was added to each well to indicate amount of the IL-1 produced as a result of adding the LPS inflammation stimulator in presence or absence of the mentioned ingredients. Thereafter, 100 microliters of a stop solution, such as hydrochloric or sulfuric acid, was added to stop the reaction.
- a stop solution such as hydrochloric or sulfuric acid.
- the reaction of the substrate solution (TMB) and the horseradish peroxidase conjugated to the anti-IL-1 antibody produces a colored product with specific spectral absorbance at wavelength of 450 nm.
- the amount of IL-1 present is determined by measuring the amount of absorbance at 450 nm resulting from the amount of bound enzyme conjugated anti-IL-1 antibody depending on the amount of IL-1 present.
- the calibration standard samples were subjected to the same protocol as the supernatant samples to determine the IL-1 present in those calibration samples.
- the optical density of the calibration standard samples was tested to establish a known absorbance of IL-1 at varying levels, for example, 1500 to 50, 125, 62.5, 31.2 and 0 picograms per milliliter in calibration dilutent.
- the optical density of the standard calibration samples were then plotted to determine a standardized IL-1 absorbance calibration curve.
- the absorbance was plotted against the standard IL-1 absorbance calibration curve to determine the amount of IL-1 present in the sample supernatant.
- composition of the invention was tested to (a) evaluate the effectiveness of these ingredients in reducing and/or inhibiting the secretion or production of cytokines, for example, IL-1 ; (b) evaluate interaction of the other ingredients with optional primary ingredients (rosehips, artichoke extract, olive extracts and nettle root); and (c) evaluate the effects of the other ingredients on interleukin cytokine, e.g., IL-1 , response in hepatocytes by measuring the C reactive protein (CRP) secretion by hepatocytes.
- cytokines for example, IL-1
- optional primary ingredients rosehips, artichoke extract, olive extracts and nettle root
- CRP C reactive protein
- the other ingredients tested were: blackberry extract, blueberry extract, cranberry extract, rosemary extract, clove extract and resveratrol.
- Table IV demonstrates the results of these other ingredients for dose specific inhibition of IL- 1 ⁇ secretion upon activation via LPS in absence or presence of additional 4 primary ingredients at low dose.
- the methodology used to test the inhibition of IL-1 ⁇ secretion is the same as that in Example 1 for the ingredients tested there.
- rosemary extract, blueberry extract, elderberry extract, cranberry extract had IL-1 modulatory effects at relatively low dose (ranging from 20-70 ug/ml).
- the IL-1 response effects were evaluated in hepatocytes by measuring the secretion of CRP when the hepatocytes were exposed to IL-1 ⁇ and IL-6 with or without pre-treatment with varying doses of the other ingredients.
- CRP secretion was chosen because, as noted above, CRP is a significant acute-phase protein in humans; its plasma concentration increases more than 1000-fold during severe trauma and/or inflammation; and CRP is expressed, e.g., synthesized or secreted, in hepatocytes in response to IL-1 and IL-6 under inflammatory conditions.
- CRP acts as a biomarker for interleukin cytokines, and it is efficient to measure this biomarker rather than the cytokines themselves because cytokine levels in the blood frequently do not accurately reflect the actual amount of the cytokines in the body.
- CRP secreted by the hepatocytes the degree of cells' response to IL-1 and/or IL-6 is able to be determined.
- hepatocytes now dosed with the ingredient, were returned to the incubator and incubated for 4 hours under the same conditions.
- a known CRP inducer such as IL-1 and/or IL-6 was added to each well plate to a final concentration of 1 nanograms/ml.
- the IL treated cultures were returned to the incubator for an additional 16 hours. After the incubation, the supematants were then labeled and organized for CRP detection.
- each supernatant was tested for presence of CRP according to a conventional CRP testing protocol provided by the supplier of the tests, Life Diagnostics, Inc. of West Chester, Pennsylvania. The specific protocol is provided in the reference, High Sensitivity C-Reactive Protein Enzyme Immunoassay Test Kit, (2003), available from Life Diagnostics, Inc., which is hereby incorporated by reference.
- TMB substrate solution
- a stop solution such as hydrochloric or sulfuric acid
- the calibration standard samples were subjected to the same protocol as the supernatant samples to determine the CRP present in those calibration samples.
- the optical density of the calibration standard samples was tested to establish a known absorbance of CRP at varying levels, for example, 0, 0.005, 0.01 , 0.025, 0.05, and 0.1 microgram per milliliter in calibration diluent.
- the optical density of the standard calibration samples were then plotted to determine a standardized CRP absorbance calibration curve.
- the absorbance was plotted against the standard CRP absorbance calibration curve to determine the amount of CRP present in the sample supernatant.
- the results of the CRP inhibitory potential of the various ingredients was recorded as noted in Table III below. As indicated there, the results are reported in EC50 values, which is a commonly accepted measurement of effective dosages. Generally speaking, the EC50 is the concentration of ingredients required to cause 50% change in CRP concentrations (e.g., a reduction in CRP or an inhibition of CRP synthesis) when compared to control samples
- In vivo testing will be conducted on approximately 150-200 human subjects by administering a composition of the invention in daily dosages over a twenty week period. More specifically, the composition will be tested to evaluate (a) the inhibition of IL-1 synthesis in Pattern 1 individuals, and (b) evaluate the inhibition of IL-1 response as measured by CRP levels in Pattern 2 individuals having CRP levels above 3 mg CRP/L blood.
- Pattern 1 individuals are humans who have of IL-1 genotypes known to possess "normal” or “exaggerated” IL-1 gene expression responses.
- the exaggerated IL-1 gene expression genotype is defined as the presence of at least one copy of allele 2 at the +3954 locus of the IL-1 ⁇ gene or two copies of allele 2 at the +4845 locus of the IL-1 ⁇ gene.
- Pattern 2 individuals are humans who have elevated blood levels of inflammation biomarkers, for example, CRP levels of about 3 to about 10 mg/L or more. With this range of CRP, there appears to be a greater opportunity for observing noticeable improvement, i.e., reduction of CRP levels. In other words, it likely will be possible to detect modest decreases in CRP in Pattern 2 subjects.
- composition of the invention that will be administered to fifty test subjects in tablet form daily will include rosehips, blackberry and blueberry, in the daily amounts: 1200 mg rosehips, 165 mg blackberry and 330 mg blueberry.
- Another composition of the invention that will be administered to fifty test subjects will include rosehips, blackberry, blueberry and Aframomum melegueta, in the daily amounts: 1200 mg rosehips, 165 mg blackberry, 330 mg blueberry and 300 mg Aframomum melegueta. These ingredients will be in tablet form.
- a further composition of the invention that would be administered to 50 test subjects will include rosehips, Aframomum melegueta and resveratrol (e.g., Resveravine ® , a resveratrol product commercially available from Bio Serae of Bram, France) in the daily amounts 1200 mg rosehips, 150 mg Aframomum melegueta and 40 mg resveratrol. These ingredients will be in tablet form.
- a placebo, including no ingredients of the composition will be administered daily in tablet form to fifty subjects.
- the first twelve weeks of administering the above compositions and placebo to the respective subjects will be the double blind phase of the testing. During this phase the dosages above will be the. loading dose. After the twelfth week, the single blind phase of testing will begin. During this phase, the dosages above may be altered to maintenance dosages, which will be extrapolated from the loading phase data.
- blood samples will be taken from the subjects to measure IL-1 and CRP.
- This blood sampling will be controlled, however, to quantify and minimize intra-individual variability.
- inflammation biomarkers such as CRP
- gene expression outcomes such as the transcription and subsequent synthesis of IL-1
- samples from women will be obtained during the same week as those subjects' monthly menstrual cycle.
- This CRP monitoring protocol suggests taking multiple sampling on different, proximate days.
- first and second compositions will be evaluated by ex vivo IL-1 production inhibition (see methods above), in vivo IL-1 gene expression, and blood levels of inflammatory biomarkers, e.g., IL-6, TNF, IL-10, IL-12, Serum Amyloid A, Fibrinogen, ICAM-1 , C reactive protein, etc.
- inflammatory biomarkers e.g., IL-6, TNF, IL-10, IL-12, Serum Amyloid A, Fibrinogen, ICAM-1 , C reactive protein, etc.
- in vivo IL-1 gene expression will be evaluated by measuring the amount of IL-1 mRNA in subject leukocytes by rtPCR.
- Evidence of an effective intervention for regulation of the inflammatory process include inhibition of ex vivo IL-1 production, inhibition of in vivo IL-1 gene expression, and decreased levels of one or more inflammatory biomarkers as listed above.
- Fig. 1 illustrates how inflammation and interleukin cytokines contribute to atherosclerotic plaque development.
- mononuclear leukocytes 10 enter artery wall tissue 100, engulf oxidized lipids, recruit additional leukocytes 14 with inflammatory cytokines, e.g., IL-1 , stimulate plaque growth 30 via growth factors, which results in stenosis.
- cytokines e.g., IL-1
- the cytokines 20 released by the leukocytes within the plaque lead to plaque instability, and can ultimately cause rupture and thrombosis.
- IL-1 200 synthesizes the cytokines 20, which in turn stimulate liver 50 production of acute phase proteins, e.g., CRP.
- acute phase proteins e.g., CRP.
- the composition of the invention inhibits the production of the cytokines 200 by the leukocytes 10.
- Specific ingredients 500 e.g., rosehips, blueberry and elderberry, can be targeted to perform this function.
- the composition of the invention may also inhibit the response 300 of cells and/or the liver 50 to the cytokines by reducing or eliminating the synthesis of CRP.
- Specific ingredients 600 e.g., blackberry, resveratrol, Aframomum melegueta and/or astaxanthin can be targeted to perform this function.
- EXAMPLE 4 e.g., blackberry, resveratrol, Aframomum melegueta and/or astaxanthin can be targeted to perform this function.
- compositions of the present invention were periodically evaluated in 120 human subjects over twelve weeks using a double blind, placebo-controlled trial.
- effects of the compositions of the present invention on recognized markers of inflammation such as plasma levels of C-reactive protein (CRP), as well as other markers of inflammation, such as ex vivo IL-1 production and in vivo IL-1 synthesis and/or expression, were evaluated.
- markers of inflammation such as plasma levels of C-reactive protein (CRP)
- CRP C-reactive protein
- other markers of inflammation such as ex vivo IL-1 production and in vivo IL-1 synthesis and/or expression
- a subject having an IL-1 non-Pattern 1 genotype may have any genotype other than Pattern 1 as defined herein.
- Group 1 comprised 10 subjects of Pattern 1 genotype and 22 subjects of non-Pattern 1 genotype.
- Group 1 was administered composition 1 , as described below in Table V.
- Group 2 comprised 9 subjects of Pattern 1 genotype and 22 subjects of non-Pattern 1 genotype.
- Group 2 was administered composition 2, as described below in Table V.
- Group 3 comprised 10 subjects of Pattern 1 genotype and 20 subjects of non- Pattern 1 genotype.
- Group 3 was administered composition 3, as described below in Table V.
- Group 4 comprised 12 subjects of Pattern 1 genotype and 15 subjects of non-Pattern 1 genotype.
- Group 4 was administered a placebo.
- Table V lists the ingredients of each composition of the present invention tested in this trial, as well as the dosage regimen for each.
- Table V Compositions of Tablets and Dosage Regimens for Tablets
- compositions 1-3 All tablets comprising a composition of the present invention (Compositions 1-3), and all placebo tablets were identical in appearance.
- Inert excipients such as microcrystalline cellulose, corn starch, dicalcium phosphate and processing aids such as modified cellulose gum, magnesium stearate and silicon dioxide were added to the tablets comprising the compositions of the present invention to allow processing of the compositions into tablets.
- Placebo tablets matched the tablets of Compositions 1 , 2, and 3 in size and appearance.
- the placebo tablets contained a combination of inert excipients.
- the placebo tablets may have contained one or more of microcrystalline cellulose, corn starch, dicalcium phosphate, and processing aids such as modified cellulose gum, magnesium stearate and silicon dioxide.
- processing aids such as modified cellulose gum, magnesium stearate and silicon dioxide.
- serum levels of various molecules including CRP, glucose, creatinine, uric acid, SGOT, SGPT, total bilirubin, albumin, sodium chloride, BUN, calcium, LDH, alkaline phosphatase, total protein, potassium, CO 2 , GGT, phosphorus, magnesium, and CPK were analyzed. Any subject who showed abnormal serum levels was re-tested approximately a week later. Further, a panel of cytokine inflammatory biomarkers, including IL-1 ⁇ , TNF- ⁇ , IL-6, IL-8, IL-10, and IL-12 was analyzed for each subject on approximately a bi-weekly basis.
- blood and urine samples were taken from each subject and hemoglobin, hematocrit, and a blood count were measured for each blood sample, while the urine sample was analyzed for color, specific gravity, pH, protein, glucose, ketones, bilirubin, nitrite, leukocyte esterase, urobilinogen, white blood cells, epithelial cells, and bacteria.
- blood sampling was controlled to quantify and minimize intra-individual variability. For example, as outlined above, inflammation biomarkers, such as CRP, and gene expression outcomes, such as the transcription and subsequent synthesis of IL-1 , were measured in multiple, fasting blood samples.
- Blood samples from female subjects were obtained during the same week as those subjects' monthly menstrual cycle. This method of blood sampling is designed to control acutely increased expression of inflammation biomarkers, which often occurs in response to high fat meals and during menstrual cycles. [00125] Periodically, e.g.
- FIGS. 4-15 are normalized to baseline values, and are expressed as a fraction or fold of baseline value (percent of baseline divided by 100).
- Figure 5 shows that after twelve weeks of administration of Compositions 1 , 2, and 3, in the total study population there was a decrease in CRP synthesis and/or expression compared with administration of a placebo.
- Figure 7 As shown in Figure 7, when CRP response in Pattern 1 subjects was analyzed separately from response in non-Pattern 1 test subjects, there was a pronounced difference between all active treatments versus baseline and placebo.
- Figure 8 illustrates that ex vivo IL-1 synthesis was slightly decreased compared to placebo and baseline levels following twelve weeks of administration of
- Composition 2 comprises Rosehips
- Figures 4, 6, 9, 11 , 13, and 15 illustrate that the test subjects who were administered a placebo experienced a sharp increase in CRP expression levels, IL-1 ex vivo expression levels, and IL-1 gene expression levels after four weeks of administration. Without being limited to any theory, it is believed that this sharp increase may have been due to a change in the dietary habits of the test subjects.
- the change in dietary habits may be due to the concurrence of certain holidays and the clinical trial.
- each of Figures 4, 6, 9, 11 , 13, and 15 also illustrate that the test subjects who were administered any of Compositions 1 , 2, or 3 did not exhibit the sharp increase in CRP expression levels, ex vivo expression levels of IL-
- compositions 1 , 2, and 3 did not always reduce CRP expression levels, ex vivo expression levels of IL-1 , or IL-1 gene expression levels, each of Compositions 1 , 2, and 3 did modulate the immune response by preventing a sharp increase in expression levels of CRP and IL-1.
- This modulatory effect may be seen in Figures 4, 6, 9, 11 , 13, and 15 at the 4 week marker.
- Composition 2 which comprises rosehips + berries + Resveravine ® (Resveravine ® is a resveratrol product commercially available from Bio Serae of Bram, France), selectively down regulates IL-1 gene activity, including synthesis and expression, in subjects having a Pattern 1 genotype.
- Composition 2 which comprises rosehips + berries + Resveravine ® (Resveravine ® is a resveratrol product commercially available from Bio Serae of Bram, France)
- IL-1 gene activity including synthesis and expression
- the magnitude and temporal pattern of IL-1 gene expression, IL-1 production, and CRP expression and/or synthesis observed in this example are consistent with the current paradigm wherein exaggerated IL-1 gene responses account for an augmented inflammatory environment in subjects having a Pattern 1 genotype.
- compositions including these ingredients can be administered to subjects to modulate inflammatory responses by modulating mediators of inflammation, such as interleukin cytokines. More specifically, it is evident that the compositions of the present invention can be used to specifically inhibit synthesis of an interleukin cytokine, such as interleukin-1 (IL-1 ), for example, by inhibiting mRNA transcription of IL-1. Further, as evidenced by the results reported herein, the compositions of the present invention can be used to specifically inhibit the expression/secretion of interleukin cytokines such as IL-1.
- IL-1 interleukin-1
- compositions of the present invention can modulate an inflammatory response by decreasing synthesis and/or expression/secretion of a biomarker of inflammation such as CRP.
- a decrease in synthesis and/or expression/secretion of CRP inhibits the response of CRP to interleukin cytokines in the body of the subject.
- compositions of the present invention can modulate the immune response by preventing increases in expression, synthesis, and/or secretion levels of mediators of inflammation, such as CRP and IL-1.
- compositions of the present invention achieved a reduction in IL- synthesis and expression, as well as a reduction in CRP synthesis and/or expression/secretion in the overall subject population.
- compositions of the present invention occurred in the subject population having a Pattern 1 genotype.
- daily administration of Composition 2 e.g.
- Rosehips, berries and Resveravine ® (Resveravine ® is a resveratrol product commercially available from Bio Serae of Bram, France) in the disclosed dosage amounts) achieved a reduction in IL-1 gene expression of approximately 80% (relative to baseline) and a reduction of approximately 50% in the expression of the inflammatory biomarker CRP after twelve weeks in the subject population having a Pattern 1 genotype.
- compositions of the invention can be used to modulate the inflammatory response associated with diseases and/or abnormal conditions.
- the compositions of the present invention may be used to modulate the inflammatory response in subjects suffering from arthritis, cardiovascular conditions, osteoporosis, Alzheimer's disease, an inflammatory response to a traumatic injury, or any other abnormal conditions or diseases associated with inflammation or immunomodulatory responses, such as pain and stiffness associated with inflammation.
- osteoporosis has been linked to abnormally high
- IL-1 release levels are contemplated within this invention. Therefore, contemplated within this invention is a method for treating osteoporosis by modulating IL-1 synthesis and expression through administration of a therapeutically effective amount of the composition of the invention.
- inflammation in cardiovascular diseases is associated with increased synthesis and expression levels of IL-1.
- Expression of IL-1 triggers synthesis, expression and secretion of
- CRP which is believed to stimulate further IL-1 synthesis and/or expression.
- composition 2 which is shown to reduce levels of CRP by approximately 50% and reduce levels of IL-1 gene activity by approximately 80%, is useful in modulating an inflammatory response and thereby treating cardiovascular conditions.
- the IL-1 regulating composition of the invention may be used to limit or to control an inflammatory response due to surgery, trauma and allergic reactions involving the skin, lungs, eyes, ears, nose, throat, digestive tract, nervous system and the like.
- the composition may be used to treat mental problems, headaches and earaches, as well as debilitating neurological diseases such as Alzheimer's diseases.
Abstract
A composition for modulating cytokines to regulate an inflammatory or immunomodulatory response. The composition can include at least one of rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract, grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract and ferulic acid. Specifically, a composition of the invention can include: rosehips and at least one of blackberry, blueberry, elderberry, and optionally krill oil; or rosehips, resveratrol and at least one of Aframomum melegueta and astaxanthin. Based on the cytokine modulation and cytokine response inhibition of the composition, it can be used to regulate an immunomodulatory and/or inflammatory response, and subsequently treat diseases and/or abnormal conditions associated with inflammatory response, for example, cardiovascular conditions, arthritis, osteoporosis and Alzheimer's disease.
Description
CYTOKINE MODULATORS AND RELATED METHODS OF USE
[0001] This application is a continuation-in-part of US Patent Application Serial No. 1 1/200,412, filed August 8, 2005, which is a continuation-in-part of US Patent Application Serial No. 10/938,093, filed September 10, 2004 and PCT Application Serial No. PCT/IB2004/051742, filed September 10, 2004, and claims the benefit of US Provisional Application Serial No. 60/502,755, filed September 12, 2003 and US Provisional Application Serial No. 60/710,730, filed August 23, 2005, all of which are hereby incorporated in their entirety by reference. BACKGROUND
[0002] The present invention relates to inflammation within the body, and more particularly, to regulating inflammation to treat conditions and diseases associated therewith.
[0003] Inflammation has been linked to a variety of conditions and diseases that affect the body. For example, inflammation within joints is known to worsen the symptoms of and structural deformities caused by arthritis and rheumatoid diseases, such as bursitis, tendonitis, myositis and osteoarthritis, as well as bone and joint destructive diseases, such as osteoporosis.
[0004] Inflammation also is known to contribute to a variety of cardiovascular and metabolic disease processes, such as atherosclerosis, thrombosis, and insulin resistance associated with obesity. Atherosclerosis may increase the chances of stroke and myocardial infarction and insulin resistance may lead to diabetes. [0005] Inflammation is also thought to contribute to the development of neurological disorders, for example, Alzheimer's disease.
[0006] Indeed a large body of research now links inflammation with a wide variety of chronic degenerative diseases. This research has identified certain cells-- macrophages-that produce pro-inflammatory chemicals— cytokines—which induce signaling cascades that provide an inflammatory response. These cytokines play a role in inflammatory reaction in response to foreign and infectious agents, traumatic or chronic injury, and abnormal chemical or physical stresses.
[0007] Accordingly, treatments have been developed to regulate the release of inflammatory cytokines, or the signaling of inflammatory cytokines, specifically the interleukin-1 (IL-1 ) cytokine from macrophages. For example, U.S. Patent 5,635,478 to Vignery discloses the use of calcitonin gene related peptide (CGRP) to regulate IL-1 release, and thereby treat rheumatoid arthritis. Although highly specific CGRP is effective at regulating IL-1 , its use is cost prohibitive and presently it is undetermined whether this compound has a toxic effect with prolonged use.
BRIEF SUMMARY
[0008] The aforementioned problems are overcome in the present invention which provides a composition that regulates interleukin cytokines and/or regulates a physiological response caused by interleukin cytokines. This regulation is effective in controlling an immune response and/or an inflammatory condition. In one aspect, the composition can comprise rosehips and at least one of blackberry, blueberry and elderberry. In further aspect, the composition can comprise rosehips, resveratrol, and at least one of blackberry, blueberry, elderberry, and cranberry. In a further aspect, the composition can comprise rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, elderberry, and cranberry. In another aspect, the composition can comprise rosehips and krill oil. In yet another aspect, the composition can comprise rosehips, blackberry, blueberry, elderberry and krill oil. In a further aspect, the composition can comprise rosehips, resveratrol and Aframomum melegueta. In another aspect, the composition can comprise rosehips, at least one of resveratrol and viniferin, and Aframomum melegueta. In an even further aspect, the composition can comprise rosehips, resveratrol and astaxanthin. In another aspect, the composition can comprise rosehips, Aframomum melegueta, and at least one of blackberry, blueberry, elderberry, and cranberry. [0009] In a further aspect, the composition can comprise at least one ingredient chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocothenols,
evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid. In a more specific aspect, the composition can comprise rosehips, nettle root, olive extract and artichoke. In yet another specific aspect, the composition can comprise rosehips, resveratrol and astaxanthin.
[0010] In another aspect, the invention can provide methods for modulating or controlling an immune response and/or an inflammatory condition in a subject, the method comprising administering to the subject an effective amount of the composition of the invention to modulate or control the immune response and/or the inflammatory condition. In a specific aspect, the composition can inhibit the function of an immunomodulatory or pro-inflammatory cell, for example, a macrophage and/or a leukocyte. In a more specific aspect, the composition can inhibit the expression of the genes that produce interleukin cytokines, for example, by preventing the genetic transcription of those genes. In an even more specific aspect, the composition can inhibit the interleukin cytokine inflammation response mechanism. In another specific aspect, the composition can modulate expression of an immunomodulatory or pro-inflammatory cell, for example by preventing an increase in expression, secretion, and/or synthesis levels of an immunomodulatory or pro-inflammatory cell. In these aspects, the composition can modulate or control pro-immunomodulatory and/or pro-inflammatory responses in skeletal mass, joints, muscle, tissue, arteries, veins, capillaries, and other organs, systems and/or cells.
[0011] In a further aspect, the invention can provide a method of regulating and/or controlling the function of immune cells, such as macrophages, leukocytes and lymphocytes, by administering an effective amount of the composition to a subject. [0012] In another aspect, the invention can provide a method for regulating cytokine release, also referred to as secretion, from cells in a subject by administering to a subject a composition that modulates the synthesis, expression, or secretion of a mediator of inflammation.
[0013] In yet another aspect, the invention can provide a method that inhibits the response of cells to an interleukin cytokine by administering to a subject an effective amount of the composition of the invention. In a specific aspect, this administration can modulate the production of inflammation biomarkers, for example, C reactive
protein, which is a biomarker produced by the liver that is indicative of excessive inflammation in the body.
[0014] In a further aspect, the invention can provide a method for treating a disease or abnormal condition caused by inflammation by administering a therapeutically effective amount of the composition. In a specific aspect, the disease or abnormal condition includes at least one of a cardiovascular disease or condition, thrombosis, a metabolic condition related to insulin resistance and obesity, a traumatic injury, arthritis, osteoporosis, and Alzheimer's disease. In a more specific aspect, the method can include administering the composition to a subject having an inflammatory condition to relieve or eliminate pain, tenderness, infection and/or discomfort following traumatic injuries, surgery or other events that may cause inflammation.
[0015] The present invention provides a composition and related methods for treating a variety of immunomodulatory- and inflammation-based conditions, symptoms and diseases. Because the ingredients used are readily available and relatively inexpensive, the present invention provides a simple and cost-effective solution for treating a variety of inflammation-caused ailments and conditions. Furthermore, because the ingredients are relatively stable, many can be mixed with other materials and provided in a multipurpose supplement or food product. [0016] These and other objects, advantages and features of the invention will be more readily understood and appreciated by reference to the drawings and the detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Fig. 1 is a sectional view of a blood vessel of a subject having atherosclerotic plaque development before being treated with the composition of the present invention in Example 3;
[0018] Fig. 2 is a second sectional view of the blood vessel and a liver of a subject that illustrates the effects of interleukin cytokines in atherosclerotic plaque development in Example 3; and
[0019] Fig. 3 is a third sectional view of the blood vessel and the liver of a subject that illustrates the effects of the composition on interleukin cytokines in atherosclerotic plaque development in Example 3.
[0020] Figure 4 is a line graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression Levels in the Total Study Population. In Figure 4, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 4 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
[0021] Figure 5 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression in the Total Study Population. In Figure 5, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 5 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
[0022] Figure 6 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression Levels in Test Subjects having a Pattern 1 Genotype. In Figure 6, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 6 are based on the daily administration of the following compositions for twelve consecutive
weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
[0023] Figure 7 is a graph illustrating Baseline vs. 12 Weeks Normalized CRP Expression in Test Subjects Having a Pattern 1 Genotype. In Figure 7, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 7 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta. [0024] Figure 8 illustrates Baseline vs. 12 Weeks Normalized Ex vivo IL-1 Expression in the Total Study Population. In Figure 8, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum metegueta, and "R" indicates resveratrol. The results reported in Figure 8 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
[0025] Figure 9 illustrates Baseline vs. 12 Weeks Normalized Ex vivo IL-1 Expression in Human Subjects Having a Pattern 1 Genotype. In Figure 9, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of
blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 9 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
[0026] Figure 10 illustrates Baseline vs. 12 Weeks Normalized Ex vivo IL-I Expression in Human Subjects Have Pattern 1 Genotype. In Figure 10, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum metegueta, and "R" indicates resveratrol. The results reported in Figure 10 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta. [0027] Figure 11 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene Expression in the total study population. In Figure 1 1 , "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 11 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo. [0028] Figure 12 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene
Expression in the total study population. In Figure 12, "RH" indicates Rosehips, "B"
indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum metegueta, and "R" indicates resveratrol. The results reported in Figure 12 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta.
[0029] Figure 13 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene Expression in Test Subjects having a Pattern 1 Genotype. In Figure 13, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 13 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
[0030] Figure 14 illustrates Baseline vs. 12 Weeks Normalized IL-1 Gene Expression in Test Subjects having Pattern 1 Genotype. In Figure 14, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum metegueta, and "R" indicates resveratrol. The results reported in Figure 14 are based on the daily administration of the following compositions for twelve consecutive weeks: the first bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; the second bar is based on administration of 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; the third bar is based on administration of 1200 mg of rosehips, 40 mg of
resveratrol, and 300 mg of Aframomum melegueta. The results reported in Figure 14 demonstrate that Composition 2 (second bar) significantly inhibits expression and/or synthesis of IL-1 in test subjects having a Pattern 1 genotype. [0031] Figure 15 illustrates Baseline vs. 12 Weeks Normalized 11-1 Gene Expression in Test Subjects having a non-Pattern 1 Genotype. In Figure 15, "RH" indicates Rosehips, "B" indicates a berry ingredient selected from at least one of blackberry, blueberry, elderberry, and cranberry, "AM" indicates Aframomum melegueta, and "R" indicates resveratrol. The results reported in Figure 15 are based on the daily administration of the following compositions for twelve consecutive weeks: 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 300 mg Aframomum melegueta extract; 1200 mg rosehips, 165 mg blueberry powdered extract, 332 mg blackberry powdered extract, and 40 mg of resveratrol; 1200 mg of rosehips, 40 mg of resveratrol, and 300 mg of Aframomum melegueta; or placebo.
DETAILED DESCRIPTION
[0032] I. The Composition
[0033] A composition of the invention can include one or more ingredients chosen from rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract (epigallocatechin gallate), grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract (chlorogenic acid), and ferulic acid. Specifically, a composition of the invention can include rosehips and at least one of blackberry, blueberry, elderberry and krill oil. A composition also can include rosehips, resveratrol and Aframomum melegueta. Another composition can include rosehips, resveratrol and astaxanthin. Further, a composition of the present invention can include rosehips, Aframomum melegueta, and at least one of viniferin and resveratrol. A further composition of the invention can include rosehips,
Aframomum melegueta, and at least one of blueberry, blackberry, elderberry, and
cranberry. Another composition can include rosehips, resveratrol and at least one of blueberry, blackberry, elderberry, and cranberry. A further composition can include rosehips, at least one of viniferin and resvertrol, and at least one of blueberry, blackberry, elderberry, and cranberry. The composition can be administered in any of the dosages recited herein to inhibit cytokine expression, production, reception, secretion and/or release, as well as inhibit the cytokine response, thereby reducing or eliminating an immunomodulatory and/or inflammatory response. [0034] Acceptable dosages of the ingredients that may be effective at modulating cytokines, for example, regulating the production, reception, secretion and/or release of exemplary cytokines, such as IL-1 and/or IL-6, are presented in Table I below. Each dosage in Table I is an estimated effective daily dosage in milligrams. Furthermore, all the dosages in Table I are presented in ranges of from about the recited lower limit to about the upper limit. For example, the nettle Dosage A recites "250-2500", which represents a dosage of about 250 to about 2500 milligrams of nettle per day.
Table I: Acceptable Dosages for Ingredients to Modulate Cytokines
[0035] The ingredients identified above in Table I are readily commercially available. Depending on the application and/or the supplier, the ingredient may be an extract of a specific potency, a pure ingredient, an ingredient mixed with excipients, and in a variety of physical forms, e.g., liquid or powder. The ingredient identified as INM-176 is a compound of unknown composition available from Scigenic Company, Ltd. of Seoul, Korea.
[0036] More particularly, the composition can include one or more than one rosehip ingredient. Examples of rosehip ingredients include, without limitation, dried rosehips, rosehip oil, and rosehip extracts. A rosehip ingredient can be obtained from any of the multiple species of plants that belong to the Rosa family, for example Rosa canina. Moreover, rosehips can include the fruit, petals and/or seeds of the Rosa plants.
[0037] Any method can be used to prepare a rosehips ingredient. As an example, conventional harvesting and drying methods can be used to prepare dried rosehips. Rosehip oil can be produced with standard methods and processed with cellulose for tableting or powdered compositions. In addition, rosehips can be obtained commercially from MB North America of Torrance, California. [0038] A composition of the invention can contain one or more than one rosehips ingredient. For example, a dietary supplement can contain dried rosehips as well as rosehips extract. In addition, a composition can contain any amount of a rosehips component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a rosehips ingredient. Typically, a composition contains between about 500 mg and about 5000 mg of a rosehips ingredient and acceptably between about 500 mg and about 1500 mg.
[0039] Even more particularly, the composition can include one or more than one blackberry ingredient. Examples of blackberry ingredients include, without limitation, dried blackberry, blackberry powder, and blackberry extracts. A blackberry ingredient can be obtained from any of the multiple species of plants that belong to the Rubus family, for example Rubus fruticosus.
[0040] Any method can be used to prepare a blackberry ingredient. As an example, conventional harvesting, drying and powdering methods can be used to prepare blackberry powder. In addition, blackberry can be obtained commercially from Van Drunen Farms Futureceuticals of Santa Rosa, California. [0041] A composition of the invention can contain one or more than one blackberry ingredient. For example, a dietary supplement can contain blackberry powder as well as blackberry extract. In addition, a composition can contain any amount of a blackberry component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a blackberry ingredient. Typically, a composition contains between about 100 mg and about 1000 mg of a blackberry ingredient. [0042] Further particularly, the composition can include one or more than one blueberry ingredient. Examples of blueberry ingredients include, without limitation, dried blueberry, blueberry powder, and blueberry extracts. A blueberry ingredient can be obtained from any of the multiple species of plants that belong to the Vaccinium family, for example, Vaccinium corymbosum. [0043] Any method can be used to prepare a blueberry ingredient. As an example, conventional harvesting, drying and powdering methods can be used to prepare blueberry powder. In addition, blueberry can be obtained commercially from Van Drunen Farms Futureceuticals of Santa Rosa, California. [0044] A composition of the invention can contain one or more than one blueberry ingredient. For example, a dietary supplement can contain blueberry powder as well as blueberry extract. In addition, a composition can contain any amount of a blueberry component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a blueberry ingredient. Typically, a composition contains between about 200 mg and about 2000 mg of a blueberry ingredient.
[0045] Even more particularly, the composition can include one or more than one elderberry ingredient. Examples of elderberry ingredients include, without limitation, elderberry extracts, dried elderberry and elderberry powder. An elderberry ingredient can be obtained from any of the multiple species of plants that belong to the Sambucus family, for example, Sambucus canadensis. [0046] Any method can be used to prepare an elderberry ingredient. As an example, conventional extraction techniques can be used to prepare an elderberry extract. In addition, elderberry can be obtained commercially from Artemis International of Fort Wayne, Indiana.
[0047] A composition of the invention can contain one or more than one elderberry ingredient. For example, a dietary supplement can contain elderberry powder as well as elderberry extract. In addition, a composition can contain any amount of an elderberry component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be an elderberry ingredient. Typically, a composition contains between about 400 mg and about 4000 mg of an elderberry ingredient. [0048] Furthermore, the composition can include Aframomum melegueta. Examples of Aframomum melegueta ingredients include, without limitation, pulverized Aframomum melegueta seeds, Aframomum melegueta powder, and Aframomum melegueta extracts.
[0049] Any method can be used to prepare an Aframomum melegueta ingredient. As an example, conventional harvesting, drying and extracting methods can be used to prepare Aframomum melegueta extracts. In addition, Aframomum melegueta can be obtained commercially from Frontier Natural Products Cooperative of Norway, Iowa.
[0050] A composition of the invention can contain one or more than one Aframomum melegueta ingredient. For example, a dietary supplement can contain Aframomum melegueta powder as well as Aframomum melegueta extract. In addition, a composition can contain any amount of a Aframomum melegueta component. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be
a Aframomum melegueta ingredient. Typically, a composition contains between about 500 mg and about 1500 mg of a Aframomum melegueta ingredient. [0051] A composition of the invention can include krill oil. Krill oil can be obtained from any member of the Euphausia family, for example Euphausia superba. Conventional oil producing techniques can be used to obtain the krill oil. In addition, krill oil can be obtained commercially from Neptune Technologies and Bioresources of Quebec, Canada.
[0052] A composition can contain any amount of krill oil. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a krill oil. Typically, a composition contains between about 300 mg and about 3000 mg of a krill oil ingredient. [0053] Where the composition includes resveratrol, the resveratrol can be obtained from an extract of grape skin or other grape components, including the grape vine. Resveratrol can be present in the composition in one or more different forms, for example, extract form and powder form. Resveratrol can be obtained commercially from Charles Bowman & Co. of Holland, Michigan. [0054] The composition can further include a resveratrol ingredient that comprises resveratrol and/or derivatives thereof. For example, a resveratrol ingredient may be any oligomer of resveratrol, such as ε-viniferin, which is a dimer of resveratrol. In a further example, the resveratrol ingredient can include resveratrol in combination with derivatives of resveratrol. In one example, the resvertrol ingredient is Resveravine® (BioSerae Laboratoires, S.A., Pare Technologique du Lauragais, Bram, France), which contains both resveratrol and ε-viniferin. [0055] A composition can contain any amount of a resveratrol ingredient. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be a resveratrol ingredient. Typically, a composition contains between about 100 mg and about 1000 mg of a resveratrol ingredient.
[0056] Where the composition includes at least one type of xanthophyll, the xanthophyll can be astaxanthin. Astaxanthin can be obtained from natural sources or synthesized. For example, astaxanthin can be obtained from algae, fungi and/or
crustaceans. One type of astaxanthin can be obtained commercially from Cyanotech Corporation of Kailua-Kona, Hawaii.
[0057] A composition can contain any amount of an astaxanthin ingredient. For example, at least about 1 percent (e.g., at least about 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, or 90 percent) of a dietary supplement can be astaxanthin. Typically, a composition contains between about 0.5 mg and about 50 mg of an astaxanthin ingredient.
[0058] The composition can include one or more pharmaceutically acceptable excipients, for example, croscarmellose sodium, maltodextrin, silicified microcrystalline cellulose, silicon dioxide, stearic acid, hydroxyl propyl methyl cellulose (HPMC), lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose and the like. Diluents and other additives such as one or more pharmaceutically acceptable binding agents, fillers, supports, thickening agents, taste-improving agents, coloring agents, preservatives, proteins, antimicrobials, chelating agents, inert gases, stabilizers, regulators, emulsifiers or mixtures thereof, can be used depending on the form of the composition employed. [0059] The ingredients of the composition can be processed into forms having varying delivery systems. For example, the ingredients can be processed and included in capsules, tablets, gel tabs, lozenges, strips, granules, powders, concentrates, solutions, lotions, creams or suspensions. The ingredients can also be administered into the respiratory tract, e.g. in the treatment of asthma, anaphylactic or and other acute shock conditions via a spray, mist or aerosol. The ingredients can be formulated, individually or in combination, with other foods to provide pre-measured nutritional supplements, supplemented foods, for example, single serving bars. In one example, the composition can include one ingredient administered in tablet form, and another ingredient administered in capsule form. More generally, the composition can be formulated for a variety of administration routes, for example, intravenously, intramuscularly, subcutaneously, nasally, sublingualis intrathecally, topically or intradermally.
[0060] The dosages of the composition may be administered in increments determined by the disease or condition being treated. For example, in the treatment of arthritis, the composition may be administered in multiple successive dosages,
spaced as frequently as about 6 to about 12 hours apart, and as long as about 2 weeks apart. Daily dosages may be administered for a period to obtain symptomatic relief from inflammatory tenderness, swelling and pain. The dosages may be adjusted to maintain the relief from these symptoms. Treatment may be a period of weeks or months, or optionally, indefinitely for chronic diseases or conditions. [0061] II. Method of Manufacturing the Composition
[0062] An exemplary composition of the invention including rosehips, blackberry powder, blueberry powder and elderberry extract can be manufactured in tablet form according to the following processes. Other administration mediums, such as gel tabs, capsules, liquid and sustained release formulations, etc. can be formulated and prepared according to manufacturing techniques well known in the pharmaceutical industry.
[0063] Rosehips, blackberry powder, and blueberry powder in the amounts recited in Dosage A in Table Il above are added to silicone dioxide and placed in a polybag and blended until uniformly and homogeneously mixed. This resultant blend is placed in a Patterson Kelley (P. K.) 100 blender available from Patterson-Kelley Co., East Stroudsburg, Pennsylvania. The following ingredients in the order listed are then passed through a Sweco separator equipped with a 20-mesh screen available from Sweco, Inc. of Florence, Kentucky directly into the P. K. 100 blender: dextrose, croscarmellose sodium, and silicified microcrystalline cellulose. The resultant composition is blended in the P. K. 100 blender for 15 minutes. [0064] A vegetable-based stearic acid powder is then passed through the Sweco separator directly into the P. K. 100 blender. The resultant mixture is blended for an additional five minutes. The resulting mixture is discharged into totes or super sacks, compressed, and punched into tablets by conventional apparatus. An acceptable range weight for each individual tablet is from about 250 mg to about 500 mg. The amount of rosehips in each tablet is about 1200 mg, the amount of blackberry is about 165 mg and the amount of blueberry is about 330 mg. Tablets manufactured according to this process can be used in the in vivo testing described herein. [0065] A soft gel capsule of the composition can be manufactured to include krill oil. This capsule can be manufactured using conventional capsule manufacturing
techniques. The amount of krill oil in each capsule is about 300 mg. These capsules can be administered alone or in conjunction with the tablets of other ingredients of the composition as part of the in vivo testing described herein. [0066] Other compositions of the invention including either rosehips and blackberry powder, or rosehips and blueberry powder, can be manufactured in tablet form according to the tableting process described above. The amount of rosehips in the rosehips/blackberry tablet is about 300 mg, and the amount of blackberry is about 80 mg. The amount of rosehips in the rosehips/blueberry tablet is about 300 mg, and the amount of blueberry is about 40 mg. Tablets manufactured according to this process can be used in the in vivo testing described herein as desired. [0067] Another composition including rosehips, resveratrol and Aframomum melegueta can be manufactured in table form according to the tableting process described above, with about 300 mg rosehips, 10 mg resveratrol and 75 mg Aframomum melegueta extract.
[0068] Another composition of the invention including rosehips, resveratrol and astaxanthin can be manufactured in table form according to the tableting process described above, with about 300 mg rosehips, 10 mg resveratrol and 1 mg astaxanthin.
[0069] Yet another composition of the invention including olive extract, artichoke, nettle root and rosehips can be manufactured in tablet form according to the following process. Olive extract, artichoke, nettle root and rosehips in the amounts recited in Dosage A in Table Il above are added to silicone dioxide and placed in a polybag and blended until uniformly and homogeneously mixed. This resultant blend is placed in a Patterson Kelley (P. K.) 100 blender available from Patterson-Kelley Co., East Stroudsburg, Pennsylvania. The following ingredients in the order listed are then passed through a Sweco separator equipped with a 20-mesh screen available from Sweco, Inc. of Florence, Kentucky, directly into the P. K. 100 blender: dextrose, croscarmellose sodium, and silicified microcrystalline cellulose. The resultant composition is blended in the P. K. 100 blender for 15 minutes. [0070] A vegetable-based stearic acid powder is then passed through the Sweco separator directly into the P. K. 100 blender. The resultant mixture is blended for an additional five minutes. The resulting mixture is discharged into totes or super
sacks, compressed, and punched into tablets by conventional apparatus. An acceptable range weight for each individual tablet is from about 250 mg to about 500 mg.
[0071] III. Selection of Ingredients for the Composition [0072] The present invention can include an ingredient screening process for selecting ingredients that are optimal for particular health conditions, and that can be used in the composition as desired. For example, in the case of a nutritional supplement for modulating IL-1 , the active ingredients can be selected via a unique screening process. The various factors include biological, commercial, regulatory, and descriptive discriminators. Some preferred discriminators and their weighted values are outlined Table 2. Preferably, the discriminators are assigned a weight based upon business or consumer driven objectives. In Table 2, a weight of 3 means that the discriminator carries heavy weighting or importance in the selection process ("Factor 3 Discriminator"); 2 means that the discriminator carries significant weight, but less than a weight factor of 3 in the selection process ("Factor 2 Discriminator"); and 1 carries the least weight as a discriminator ("Factor 1 Discriminator").
Table II: Discriminators for Selecting Cytokine Modulating Ingredients
*Fractional bioavailability is the percentage of the active compounds in an orally ingested ingredient (expressed as a fraction) that is absorbed into the body, and is generally available to body tissues via the circulation. For example, a fractional availability of 0.10 indicates that 10% of an orally ingested ingredient's actives are absorbed from the intestinal tract and are (for some period of time) transported in the circulation.
[0073] In the above example, the primary objective is to find an effective and commercially successful IL-1 modulator for human use. Selection of the best candidates is accomplished by summing the discriminator weights for each candidate and comparing total weighted score. Thus, performance of an active ingredient in modulating IL-1 is relevant, as is the expense to obtain the particular ingredient and the availability of the ingredient. Other factors relevant to commercial success are the ingredient's toxicity and safety as well as the technical and regulatory acceptance of the ingredient in the market where the composition will be sold. There may be cases where some ingredients do not meet one Factor 3 Discriminator, and the one Factor 3 Discriminator is different for each ingredient. In these cases, Factor 3 Discriminators are assigned weights and Factor 2 and Factor 1 Discriminators are also considered in the selection process. [0074] In addition to the above ingredient screening process, the therapeutic composition or ingredient is preferably subjected to an ex vivo clinical evaluation to
confirm the biological properties and effects. In particular, the subject consumes the therapeutic composition or ingredient. Serial blood samples are obtained from the subject before and following consumption over a time period when the ingredient's active components are likely to be absorbed by and transported within the circulatory system of the body, which is about 6 hours for most chemicals. These blood samples are added to an in vitro bioassay system which has an assay or test readout that is sensitive to changes in the physiology of the system of interest. The results of this test, referred to as an ex vivo test, are compared to the results from the in vitro clinical. The closer the results of the in vitro and ex vivo evaluations the greater the likelihood that the therapeutic will have desired effect within the body. [0075] IV. Cytokine Inhibitory Potential Evaluation
[0076] The ingredients of the composition can modulate cytokines via at least two different biological mechanisms. In a first mechanism, the ingredients can inhibit the production, i.e., synthesis, of interleukin cytokines. In this mechanism, it is believed that the ingredients prevent the mRNA transcription of the genes that code for the production of the interleukin cytokines. Therefore, with genetic transcription blocked, the cytokines can not be synthesized by or in the body. In a second mechanism, the ingredients can inhibit the cascading response of chemicals and cells in the body to the interleukin cytokines. More particularly, the ingredients can prevent the production of-among other compounds-acute phase proteins, for example, C reactive protein (CRP). CRP is synthesized in the human liver by hepatocytes in response to interleukin cytokines, e.g., IL-1 and IL-6, under traumatic and/or inflammatory conditions. The ingredients can affect the response mechanism of cells, for example, liver cells, to interleukin cytokines so that those cells reduce or stop production of CRP.
[0077] In the following examples, the interleukin cytokine modulating potential, in both inhibiting the synthesis of cytokines and inhibiting the response caused by cytokine, of the various listed ingredients was measured and the results of each exposure was reported and evaluated.
[0078] For this evaluation, white blood cells were dosed with varying concentrations of the ingredients. An inflammatory stimulus, lipopolysaccharide
(LPS), was then added to the ingredient-plus-cell culture, as well as untreated
control samples of white blood cells. The production of the IL-1 cytokine of both the ingredient-treated cells and the untreated cells was compared to extrapolate the concentration of the ingredient that causes a 50% change in the concentration of IL- 1 produced by the cells.
[0079] These examples are presented for purposes of further illustrating and explaining the present invention and are not to be taken as limiting in any regard. Unless otherwise indicated, all temperature measurements are in degree Celsius.
EXAMPLE 1
[0080] To perform the evaluation of inhibiting interleukin synthesis of this example, human white blood cells, specifically THP- 1 cells obtained from ATCC of Manassas, Virginia, were grown under conditions recommended by ATCC in a humidified 370C incubator, which was supplied with 5% carbon dioxide. To test the IL-1 inhibitory potential of various compounds, multiple groups of THP- 1 cells were plated in 96 well plates. Specifically, 5 X 105 THP- 1 cells were plated in RPMI 1640 supplement with 10% fetal bovine serum and antibiotics, such as penicillin and streptomycin. With these cell samples plated, they were then dosed. [0081] In dosing, each of the ingredients was administered to the plated THP-1 cells in varying doses, specifically, 100 ug/ml, 10 ug/ml, 1 ug/ml and 0 ug/ml. For example, in one plate of cells, 100 micrograms per milliliter of nettle root extract were administered, in another, 10 micrograms per milliliter were administered, in another 1 microgram per milliliter were administered, and in yet another no nettle root was administered. The THP-1 cells, now dosed with the desired ingredients, were returned to the incubator and incubated for 4 hours under the same conditions. [0082] Thereafter, a known inflammatory stimulator, lipopolysaccharide (LPS) was added to each well plate to a final concentration of 100 nanograms/ml. The LPS treated cultures were returned to the incubator for an additional 16 hours. The cultures were then centrifuged at 1000 Gs for about 5 minutes to obtain a supernatant. The supernatants were then labeled and organized for IL-1 detection. [0083] To detect secreted IL-1 in the different dosed supernatants and therefore evaluate the IL-1 secretion inhibitory potential of each dosage of each ingredient, each supernatant was tested for presence of IL-1 according to a conventional IL-1
testing protocol provided by the supplier of the tests, Biosource International of Camarillo, California. The specific protocol is provided in the reference, Protocol Booklet, Human IL-1 , (2001 ), available from Biosource International, which is hereby incorporated by reference.
[0084] In general accordance with the protocol, 50 microliters of each supernatant sample was added to each well of anti-IL-1 coated plates, which were incubated at room temperature for 2 hours. Likewise, calibration standards designed to establish known amounts of IL-1 were added to the designated wells of anti-IL-1 antibody coated plates and incubated at room temperature for 2 hours. [0085] Thereafter, the liquids from each of the wells were removed and the coated plate was washed 3 times in a wash buffer. After the third wash, 100 microliters of enzyme (horseradish peroxidase) conjugated anti-IL-1 antibody was added to each well of the coated plate and incubated at room temperature for 30 minutes. The plate was washed again as before and 100 microliters of substrate solution, (TMB), was added to each well to indicate amount of the IL-1 produced as a result of adding the LPS inflammation stimulator in presence or absence of the mentioned ingredients. Thereafter, 100 microliters of a stop solution, such as hydrochloric or sulfuric acid, was added to stop the reaction. The reaction of the substrate solution (TMB) and the horseradish peroxidase conjugated to the anti-IL-1 antibody produces a colored product with specific spectral absorbance at wavelength of 450 nm. Hence the amount of IL-1 present is determined by measuring the amount of absorbance at 450 nm resulting from the amount of bound enzyme conjugated anti-IL-1 antibody depending on the amount of IL-1 present. [0086] The calibration standard samples were subjected to the same protocol as the supernatant samples to determine the IL-1 present in those calibration samples. The optical density of the calibration standard samples was tested to establish a known absorbance of IL-1 at varying levels, for example, 1500 to 50, 125, 62.5, 31.2 and 0 picograms per milliliter in calibration dilutent. The optical density of the standard calibration samples were then plotted to determine a standardized IL-1 absorbance calibration curve.
[0087] For each sample supernatant tested and optically measured, the absorbance was plotted against the standard IL-1 absorbance calibration curve to determine the amount of IL-1 present in the sample supernatant. [0088] Based on the amount of IL-1 present in the sample supernatant, the results of the IL-1 inhibitory potential of the various ingredients was recorded as noted in Table III below. As indicated there, the results are reported in EC50 values, which is a commonly accepted measurement of effective dosages. Generally speaking, the EC50 is the concentration of ingredients required to cause 50% change in IL-1 concentrations when compared to control samples. Table III: Results of IL-1 Assays in Example 1
[0089] The results of the testing in Table III illustrate the effectiveness of these ingredients in reducing and/or inhibiting the secretion or production of cytokines, for example, IL-1.
EXAMPLE 2
[0090] In this example, other ingredients that can be included in the composition of the invention were tested to (a) evaluate the effectiveness of these ingredients in reducing and/or inhibiting the secretion or production of cytokines, for example, IL-1 ; (b) evaluate interaction of the other ingredients with optional primary ingredients (rosehips, artichoke extract, olive extracts and nettle root); and (c) evaluate the effects of the other ingredients on interleukin cytokine, e.g., IL-1 , response in hepatocytes by measuring the C reactive protein (CRP) secretion by hepatocytes.
[0091] Specifically, the release of IL-1 from the THP- 1 cells after exposure to lipopolysaccharide (LPS) with or without pre-treatment in varying doses of the other ingredients, or a combination of those other ingredients with optional primary ingredients, was measured to evaluate the effects of the other ingredients on monocyte IL-1α secretion. Hepatocytes' response to IL-1 expression levels was evaluated by measuring CRP in the culture supernatant after exposure of the hepatocytes to IL-1 and IL-6 with or without pre-treatment with varying doses of the other ingredients.
[0092] The other ingredients tested were: blackberry extract, blueberry extract, cranberry extract, rosemary extract, clove extract and resveratrol. Table IV, demonstrates the results of these other ingredients for dose specific inhibition of IL- 1α secretion upon activation via LPS in absence or presence of additional 4 primary ingredients at low dose. The methodology used to test the inhibition of IL-1α secretion is the same as that in Example 1 for the ingredients tested there. Of the ingredients tested in this Example 2, rosemary extract, blueberry extract, elderberry extract, cranberry extract had IL-1 modulatory effects at relatively low dose (ranging from 20-70 ug/ml).
[0093] Interference of the other ingredients with the IL-1 modulatory effects of the listed optional primary ingredients was tested by comparing the optional primary ingredients IL-1 secretion inhibitory effects, for example those shown in Table III, with the IL-1 secretion inhibitory effects of those primary ingredients in combination with the other ingredients listed in Table IV. For example, the presence of blackberry did not alter the IL-1 modulating effect of rosehips as illustrated by the absence of
the characteristic inhibitory activity. None of the other ingredients showed interference with the optional primary ingredients, but some showed synergistic effects (blueberry extract showed synergistic effect with rosehips and nettle root, and elderberry extract with artichoke extract and nettle root). In Table IV, a "-" indicates no interference or no synergy, and a "+" indicates interference or synergy, respectively as shown.
[0094] The IL-1 response effects were evaluated in hepatocytes by measuring the secretion of CRP when the hepatocytes were exposed to IL-1α and IL-6 with or without pre-treatment with varying doses of the other ingredients. CRP secretion was chosen because, as noted above, CRP is a significant acute-phase protein in humans; its plasma concentration increases more than 1000-fold during severe trauma and/or inflammation; and CRP is expressed, e.g., synthesized or secreted, in hepatocytes in response to IL-1 and IL-6 under inflammatory conditions. CRP acts as a biomarker for interleukin cytokines, and it is efficient to measure this biomarker rather than the cytokines themselves because cytokine levels in the blood frequently do not accurately reflect the actual amount of the cytokines in the body. Thus, by measuring CRP secreted by the hepatocytes, the degree of cells' response to IL-1 and/or IL-6 is able to be determined.
[0095] To perform the evaluation of this example, human primarily isolated hepatocyte cells, obtained from In vitro Technology of Baltimore, Maryland, were restored under the conditions recommended by In vitro Technology in a humidified 37°C incubator, which was supplied with 5% carbon dioxide. To test the CRP response potential of various compounds, multiple groups of hepatocytes were plated in 96 well plates. Specifically, 1 X 104 cells were plated in hepatocyte media supplement with 10% fetal bovine serum which were then exposed with varying doses, specifically, 100 ug/ml, 10 ug/ml, 1 ug/ml and 0 ug/ml of test ingredients. For example: in one plate of cells, 100 micrograms per milliliter of blackberry extract were administered; in another, 10 micrograms per milliliter were administered; in another 1 microgram per milliliter were administered; and in yet another no nettle root was administered. With the plated cells treated with the respective ingredients, the hepatocytes, now dosed with the ingredient, were returned to the incubator and incubated for 4 hours under the same conditions.
[0096] Thereafter, a known CRP inducer, such as IL-1 and/or IL-6 was added to each well plate to a final concentration of 1 nanograms/ml. The IL treated cultures were returned to the incubator for an additional 16 hours. After the incubation, the supematants were then labeled and organized for CRP detection. [0097] To detect secreted CRP in the different dosed supematants and therefore evaluate the CRP secretion inhibitory potential of each dosage of each ingredient, each supernatant was tested for presence of CRP according to a conventional CRP testing protocol provided by the supplier of the tests, Life Diagnostics, Inc. of West Chester, Pennsylvania. The specific protocol is provided in the reference, High Sensitivity C-Reactive Protein Enzyme Immunoassay Test Kit, (2003), available from Life Diagnostics, Inc., which is hereby incorporated by reference. [0098] In general accordance with the protocol, 10 microliters of each supernatant sample was added to well of the anti-CRP antibody coated plates along with 100 ul of second antibodies against CRP conjugated to the horse radish peroxidase, which were incubated at room temperature for 45 minutes. Likewise, calibration standards designed to establish known amounts of CRP were added to the designated wells of anti-CRP antibody coated plates along with the second anti-CRP antibodies conjugated to the HRP and incubated at room temperature for 45 minutes. [0099] Thereafter, the liquids from each of the wells were removed and the coated plate was washed 3 times in a wash buffer. After the third wash, 100 microliters of substrate solution, (TMB), was added to each wells to indicate amount of the CRP produced as a result of adding the IL-1 and IL-6, CRP inducer in presence or absence of the mentioned ingredients. Thereafter, 100 microliters of a stop solution, such as hydrochloric or sulfuric acid, was added to stop the reaction. The reaction of the substrate solution (TMB) and the horseradish peroxidase conjugated to the anti-CRP antibody produces a colored product with specific spectral absorbance at wavelength of 450 nm. Hence the amount of CRP present is determined by measuring the amount of absorbance at 450 nm resulting from the amount of bound enzyme conjugated anti-CRP antibody depending on the amount of CRP present. [00100] The calibration standard samples were subjected to the same protocol as the supernatant samples to determine the CRP present in those calibration
samples. The optical density of the calibration standard samples was tested to establish a known absorbance of CRP at varying levels, for example, 0, 0.005, 0.01 , 0.025, 0.05, and 0.1 microgram per milliliter in calibration diluent. The optical density of the standard calibration samples were then plotted to determine a standardized CRP absorbance calibration curve.
[00101] For each sample supernatant tested and optically measured, the absorbance was plotted against the standard CRP absorbance calibration curve to determine the amount of CRP present in the sample supernatant. [00102] Based on the amount of CRP present in the sample supernatant, the results of the CRP inhibitory potential of the various ingredients was recorded as noted in Table III below. As indicated there, the results are reported in EC50 values, which is a commonly accepted measurement of effective dosages. Generally speaking, the EC50 is the concentration of ingredients required to cause 50% change in CRP concentrations (e.g., a reduction in CRP or an inhibition of CRP synthesis) when compared to control samples
[00103] When IL-1 response effects were evaluated in hepatocytes in the form of CRP secretion, blackberry extract, cranberry extract and resveratrol had potent activity with EC50 of 1-10 ug/ml. Thus, these ingredients were effective at modulating IL-1/IL-6 response, specifically by reducing the synthesis of biomarkers, for example, CRP. Blueberry powder, rosemary extract and elderberry powder also had some activity in modulating IL-1/IL-6 responses. Additional, selected ingredients were tested for dose specific inhibition of CRP secretion upon activation via IL-1 and IL-6 (1 ng/ml each). Of the additional ingredients tested, 10% natural astaxanthin, Aframomum melegueta extract (w/o carrier) and Resveravine® (resveratrol) showed potent CRP lowering activity with EC50s of about 0.3, 0.6 and 0.8 ug/ml, respectively. Astaxanthin beadlet showed activity with EC50 of slightly over 1 ug/ml.
Table IV: Example 2 Results Including EC50 of Other Ingredients In
Inhibiting LPS Stimulated IL-1 Secretion, IL-1/IL-6 Stimulated CRP Secretion, and Synergistic or Antagonistic Effects With Optional Primary Ingredients
[00104] In vivo testing will be conducted on approximately 150-200 human subjects by administering a composition of the invention in daily dosages over a twenty week period. More specifically, the composition will be tested to evaluate (a) the inhibition of IL-1 synthesis in Pattern 1 individuals, and (b) evaluate the inhibition of IL-1 response as measured by CRP levels in Pattern 2 individuals having CRP levels above 3 mg CRP/L blood.
[00105] For purposes of this example, Pattern 1 individuals are humans who have of IL-1 genotypes known to possess "normal" or "exaggerated" IL-1 gene expression responses. The exaggerated IL-1 gene expression genotype is defined as the presence of at least one copy of allele 2 at the +3954 locus of the IL-1α gene or two copies of allele 2 at the +4845 locus of the IL-1 α gene. In this example, Pattern 2 individuals are humans who have elevated blood levels of inflammation biomarkers, for example, CRP levels of about 3 to about 10 mg/L or more. With this range of CRP, there appears to be a greater opportunity for observing noticeable improvement, i.e., reduction of CRP levels. In other words, it likely will be possible to detect modest decreases in CRP in Pattern 2 subjects.
[00106] One composition of the invention that will be administered to fifty test subjects in tablet form daily will include rosehips, blackberry and blueberry, in the daily amounts: 1200 mg rosehips, 165 mg blackberry and 330 mg blueberry. [00107] Another composition of the invention that will be administered to fifty test subjects will include rosehips, blackberry, blueberry and Aframomum melegueta, in the daily amounts: 1200 mg rosehips, 165 mg blackberry, 330 mg blueberry and 300 mg Aframomum melegueta. These ingredients will be in tablet form. [00108] A further composition of the invention that would be administered to 50 test subjects will include rosehips, Aframomum melegueta and resveratrol (e.g., Resveravine®, a resveratrol product commercially available from Bio Serae of Bram, France) in the daily amounts 1200 mg rosehips, 150 mg Aframomum melegueta and 40 mg resveratrol. These ingredients will be in tablet form. [00109] A placebo, including no ingredients of the composition, will be administered daily in tablet form to fifty subjects.
[00110] The first twelve weeks of administering the above compositions and placebo to the respective subjects will be the double blind phase of the testing. During this phase the dosages above will be the. loading dose. After the twelfth week, the single blind phase of testing will begin. During this phase, the dosages above may be altered to maintenance dosages, which will be extrapolated from the loading phase data.
[00111] In the in vivo testing of this example, blood samples will be taken from the subjects to measure IL-1 and CRP. This blood sampling will be controlled, however, to quantify and minimize intra-individual variability. For example, inflammation biomarkers, such as CRP, and gene expression outcomes, such as the transcription and subsequent synthesis of IL-1 , will be measured in multiple, fasting blood samples; and samples from women will be obtained during the same week as those subjects' monthly menstrual cycle. The reason for this is that it has been discovered that high fat meals and menstrual cycles acutely increases inflammation biomarkers. Further, this CRP monitoring protocol suggests taking multiple sampling on different, proximate days.
[00112] After administration, the efficacy of the placebo, first and second compositions will be evaluated by ex vivo IL-1 production inhibition (see methods above), in vivo IL-1 gene expression, and blood levels of inflammatory biomarkers, e.g., IL-6, TNF, IL-10, IL-12, Serum Amyloid A, Fibrinogen, ICAM-1 , C reactive protein, etc. in vivo IL-1 gene expression will be evaluated by measuring the amount of IL-1 mRNA in subject leukocytes by rtPCR. Evidence of an effective intervention for regulation of the inflammatory process include inhibition of ex vivo IL-1 production, inhibition of in vivo IL-1 gene expression, and decreased levels of one or more inflammatory biomarkers as listed above.
[00113] The results of the in vivo testing of this example are expected to illustrate that the composition has the effect of modulating interleukin cytokines by both inhibiting the synthesis of interleukin cytokines and inhibiting the cascading response caused by interleukin cytokines in the subjects. A particular example of this benefit will now be described in connection with a subject having atherosclerotic plaque development exacerbated by inflammation, with reference to Figs 1-3.
[00114] Fig. 1 illustrates how inflammation and interleukin cytokines contribute to atherosclerotic plaque development. Specifically, mononuclear leukocytes 10 enter artery wall tissue 100, engulf oxidized lipids, recruit additional leukocytes 14 with inflammatory cytokines, e.g., IL-1 , stimulate plaque growth 30 via growth factors, which results in stenosis. The cytokines 20 released by the leukocytes within the plaque lead to plaque instability, and can ultimately cause rupture and thrombosis.
[00115] In Fig. 2, the synthesis of IL-1 200 and the IL-1 response 300 is shown. Specifically, the leukocytes 10 synthesize the cytokines 20, which in turn stimulate liver 50 production of acute phase proteins, e.g., CRP.
[00116] With reference to Fig. 3, the composition of the invention inhibits the production of the cytokines 200 by the leukocytes 10. Specific ingredients 500, e.g., rosehips, blueberry and elderberry, can be targeted to perform this function. The composition of the invention may also inhibit the response 300 of cells and/or the liver 50 to the cytokines by reducing or eliminating the synthesis of CRP. Specific ingredients 600, e.g., blackberry, resveratrol, Aframomum melegueta and/or astaxanthin can be targeted to perform this function. EXAMPLE 4
[00117] The in vivo effects of daily administration of three different compositions of the present invention were periodically evaluated in 120 human subjects over twelve weeks using a double blind, placebo-controlled trial. In particular, the effects of the compositions of the present invention on recognized markers of inflammation, such as plasma levels of C-reactive protein (CRP), as well as other markers of inflammation, such as ex vivo IL-1 production and in vivo IL-1 synthesis and/or expression, were evaluated. All human subjects participating in this trial were at least 18 years of age, judged to be in good general health on the basis of an interview and abbreviated physical exam, willing to maintain their normal dietary and exercise habits throughout the trial, a non-smoker for at least a year, and had an average CRP level between 2 mg/L and 10 mg/L.
[00118] All human subjects analyzed in this trial fell into one of two groups, (1 ) subjects having IL-1 Pattern 1 genotype and (2) subjects havinglL-1 non-Pattern 1 genotypes. As described above, a human subject with an IL-1 Pattern 1 genotype is
generally known to possess "exaggerated" IL-1 gene expression responses. IL-1 Pattern 1 genotype is defined as the presence of at least one copy of allele 2 at the +3954 locus of the IL-1 β gene [IL-1α (4845) = 1.2 and IL-1β (+3954) = 1.2 or 2.2] or two copies of allele 2 at the +4845 locus of the IL-1α gene [IL-1α (+4845) = 2.2]. A subject having an IL-1 non-Pattern 1 genotype may have any genotype other than Pattern 1 as defined herein.
[00119] All subjects were randomly assigned to one of four groups. Group 1 comprised 10 subjects of Pattern 1 genotype and 22 subjects of non-Pattern 1 genotype. Group 1 was administered composition 1 , as described below in Table V. Group 2 comprised 9 subjects of Pattern 1 genotype and 22 subjects of non-Pattern 1 genotype. Group 2 was administered composition 2, as described below in Table V. Group 3 comprised 10 subjects of Pattern 1 genotype and 20 subjects of non- Pattern 1 genotype. Group 3 was administered composition 3, as described below in Table V. Group 4 comprised 12 subjects of Pattern 1 genotype and 15 subjects of non-Pattern 1 genotype. Group 4 was administered a placebo. [00120] Table V lists the ingredients of each composition of the present invention tested in this trial, as well as the dosage regimen for each.
Table V: Compositions of Tablets and Dosage Regimens for Tablets
Administered According to Example 4
[00121] Regardless of group assignment, subjects were instructed to consume the same number of tablets once daily, as illustrated by Table V. All tablets comprising a composition of the present invention (Compositions 1-3), and all placebo tablets were identical in appearance. Inert excipients such as microcrystalline cellulose, corn starch, dicalcium phosphate and processing aids such as modified cellulose gum, magnesium stearate and silicon dioxide were added to the tablets comprising the compositions of the present invention to allow processing of the compositions into tablets.
[00122] Placebo tablets matched the tablets of Compositions 1 , 2, and 3 in size and appearance. The placebo tablets contained a combination of inert excipients. For example, the placebo tablets may have contained one or more of microcrystalline cellulose, corn starch, dicalcium phosphate, and processing aids such as modified cellulose gum, magnesium stearate and silicon dioxide. [00123] During the course of the trial, each subject underwent eleven periodic (approximately weekly) analyses as outlined below. Each analysis included an abbreviated physical exam of the test subject that included measurement of vital signs, body weight, assessment of concomitant medical use, assessment of compliance with taking the administered tablets for the trial, and screening for adverse experiences. Additionally, during approximately every other periodic analysis (approximately every 2 weeks), serum levels of various molecules including CRP, glucose, creatinine, uric acid, SGOT, SGPT, total bilirubin, albumin, sodium chloride, BUN, calcium, LDH, alkaline phosphatase, total protein, potassium, CO2, GGT, phosphorus, magnesium, and CPK were analyzed. Any subject who showed abnormal serum levels was re-tested approximately a week later. Further, a panel of cytokine inflammatory biomarkers, including IL-1β, TNF-α, IL-6, IL-8, IL-10, and IL-12 was analyzed for each subject on approximately a bi-weekly basis. Even further,
during approximately the seventh and eleventh weeks, blood and urine samples were taken from each subject and hemoglobin, hematocrit, and a blood count were measured for each blood sample, while the urine sample was analyzed for color, specific gravity, pH, protein, glucose, ketones, bilirubin, nitrite, leukocyte esterase, urobilinogen, white blood cells, epithelial cells, and bacteria. [00124] In this example, blood sampling was controlled to quantify and minimize intra-individual variability. For example, as outlined above, inflammation biomarkers, such as CRP, and gene expression outcomes, such as the transcription and subsequent synthesis of IL-1 , were measured in multiple, fasting blood samples. Blood samples from female subjects were obtained during the same week as those subjects' monthly menstrual cycle. This method of blood sampling is designed to control acutely increased expression of inflammation biomarkers, which often occurs in response to high fat meals and during menstrual cycles. [00125] Periodically, e.g. at four weeks, eight weeks, and twelve weeks after initiation of administration, efficacies of the placebo, Composition 1 , Composition 2, and Composition 3 were evaluated by (a) ex vivo analysis of inhibition of IL-1 synthesis and/or expression in the test subjects (see methods above); (b) analysis of in vivo IL-1 gene expression (rtPCR was used to measure IL-1 mRNA levels in samples obtained from test subjects); and (c) analysis of serum and/or cellular synthesis and expression levels of inflammatory biomarkers, such as IL-6, TNF, IL- 10, IL-12, Serum Amyloid A, Fibrinogen, ICAM-1 , C reactive protein, etc. [00126] The results of these evaluations are reported Figures 4-15. The graphs shown in Figures 4-15 are normalized to baseline values, and are expressed as a fraction or fold of baseline value (percent of baseline divided by 100). [00127] Figure 5 shows that after twelve weeks of administration of Compositions 1 , 2, and 3, in the total study population there was a decrease in CRP synthesis and/or expression compared with administration of a placebo. [00128] As shown in Figure 7, when CRP response in Pattern 1 subjects was analyzed separately from response in non-Pattern 1 test subjects, there was a pronounced difference between all active treatments versus baseline and placebo. In particular, Composition 2 (rosehips + berries + Resveravine® ((Resveravine® is a resveratrol product commercially available from Bio Serae of Bram, France)
(P=0.0113)) inhibited CRP synthesis and/or expression at a rate of approximately
50%.
[00129] Figure 8 illustrates that ex vivo IL-1 synthesis was slightly decreased compared to placebo and baseline levels following twelve weeks of administration of
Compositions 1 , 2, and 3. No significant difference was observed between
Compositions 1 , 2, and 3.
[00130] Figure 10 illustrates that in the test subjects having a Pattern 1 genotype, there was a striking divergence of response between compositions of the present invention and placebo compositions. In particular, after twelve weeks, IL-1 production was reduced by approximately 20% - 30% in each of Groups 1 , 2, and 3 relative to baseline (P=0.0068).
[00131] As shown in Figure 12, analysis of the baseline versus 12 week data in the total subject population reveals that IL-1 gene expression was significantly reduced following administration of each of Compositions 1, 2, and 3, with the most striking result associated with administration of Composition 2 (P=O.0047).
[00132] As Figure 14 illustrates, when data for test subjects having a Pattern 1 genotype were evaluated independently, IL-1 gene expression declined by approximately 80% relative to baseline. This decline was highly significant in Group
2, which was administered Composition 2 (Composition 2 comprises Rosehips,
Berries, and Resveravine® (Resveravine® is a resveratrol product commercially available from Bio Serae of Bram, France) (P=0.0158)).
[00133] Figures 4, 6, 9, 11 , 13, and 15 illustrate that the test subjects who were administered a placebo experienced a sharp increase in CRP expression levels, IL-1 ex vivo expression levels, and IL-1 gene expression levels after four weeks of administration. Without being limited to any theory, it is believed that this sharp increase may have been due to a change in the dietary habits of the test subjects.
The change in dietary habits may be due to the concurrence of certain holidays and the clinical trial.
[00134] Significantly, each of Figures 4, 6, 9, 11 , 13, and 15 also illustrate that the test subjects who were administered any of Compositions 1 , 2, or 3 did not exhibit the sharp increase in CRP expression levels, ex vivo expression levels of IL-
1 , or IL-1 gene expression levels at point during the clinical trial. Rather, these
individuals maintained a steady or decreased state of expression of CRP and IL-1. Thus, even though Compositions 1 , 2, and 3 did not always reduce CRP expression levels, ex vivo expression levels of IL-1 , or IL-1 gene expression levels, each of Compositions 1 , 2, and 3 did modulate the immune response by preventing a sharp increase in expression levels of CRP and IL-1. One example of this modulatory effect may be seen in Figures 4, 6, 9, 11 , 13, and 15 at the 4 week marker. [00135] The results shown in Figures 4-15 demonstrate that Composition 2, which comprises rosehips + berries + Resveravine® (Resveravine® is a resveratrol product commercially available from Bio Serae of Bram, France), selectively down regulates IL-1 gene activity, including synthesis and expression, in subjects having a Pattern 1 genotype. The magnitude and temporal pattern of IL-1 gene expression, IL-1 production, and CRP expression and/or synthesis observed in this example are consistent with the current paradigm wherein exaggerated IL-1 gene responses account for an augmented inflammatory environment in subjects having a Pattern 1 genotype.
[00136] In striking contrast to the results in Pattern 1 subjects, the antiinflammatory effects observed for non-Pattern 1 subjects were much less clear. This genotype (IL-1 haplotype) differential response suggests that Composition 2 (i.e., rosehips + berries + Resveravine® (Resveravine® is a resveratrol product commercially available from Bio Serae of Bram, France)), selectively down regulates the inflammation pathway at the level of IL-1 gene activity in Pattern 1 individuals, leading to clinically meaningful decreases in established downstream markers of inflammation, e.g., CRP. [00137] V. Methods of Use
[00138] Based on the results of the testing of ingredients that can be included in compositions according to the present invention as exemplified by Examples 1-4 above, it is evident that compositions including these ingredients can be administered to subjects to modulate inflammatory responses by modulating mediators of inflammation, such as interleukin cytokines. More specifically, it is evident that the compositions of the present invention can be used to specifically inhibit synthesis of an interleukin cytokine, such as interleukin-1 (IL-1 ), for example, by inhibiting mRNA transcription of IL-1. Further, as evidenced by the results
reported herein, the compositions of the present invention can be used to specifically inhibit the expression/secretion of interleukin cytokines such as IL-1. Even further, it is evident that the compositions of the present invention can modulate an inflammatory response by decreasing synthesis and/or expression/secretion of a biomarker of inflammation such as CRP. A decrease in synthesis and/or expression/secretion of CRP inhibits the response of CRP to interleukin cytokines in the body of the subject. Still further, it also is evident that the compositions of the present invention can modulate the immune response by preventing increases in expression, synthesis, and/or secretion levels of mediators of inflammation, such as CRP and IL-1.
[00139] The results described herein demonstrate that daily administration of three different compositions of the present invention achieved a reduction in IL- synthesis and expression, as well as a reduction in CRP synthesis and/or expression/secretion in the overall subject population. However, the most striking evidence of the ability to modulate an inflammatory response utilizing compositions of the present invention occurred in the subject population having a Pattern 1 genotype. For example, daily administration of Composition 2 (e.g. Rosehips, berries and Resveravine® (Resveravine® is a resveratrol product commercially available from Bio Serae of Bram, France) in the disclosed dosage amounts) achieved a reduction in IL-1 gene expression of approximately 80% (relative to baseline) and a reduction of approximately 50% in the expression of the inflammatory biomarker CRP after twelve weeks in the subject population having a Pattern 1 genotype.
[00140] These results are significant because inflammation is a major component of numerous diseases including cardiovascular diseases. Indeed, given that inflammatory cytokines, such as IL-1 and IL-6, are key mediators of the inflammatory response in the body, it is significant that the compositions of the invention can be used to modulate the inflammatory response associated with diseases and/or abnormal conditions. For example, the compositions of the present invention may be used to modulate the inflammatory response in subjects suffering from arthritis, cardiovascular conditions, osteoporosis, Alzheimer's disease, an inflammatory response to a traumatic injury, or any other abnormal conditions or
diseases associated with inflammation or immunomodulatory responses, such as pain and stiffness associated with inflammation.
[00141] In a further example, osteoporosis has been linked to abnormally high
IL-1 release levels. Therefore, contemplated within this invention is a method for treating osteoporosis by modulating IL-1 synthesis and expression through administration of a therapeutically effective amount of the composition of the invention.
[00142] Given the connection between inflammation and cardiovascular diseases, such as atherosclerosis, thrombosis, aortic stenosis, etc. also contemplated within this invention is the treatment of such cardiovascular diseases by administering a therapeutically effective amount of the composition including at least one of the ingredients in a recited dosage. Indeed, inflammation in cardiovascular diseases is associated with increased synthesis and expression levels of IL-1. Expression of IL-1 triggers synthesis, expression and secretion of
CRP, which is believed to stimulate further IL-1 synthesis and/or expression.
Therefore, a composition of the present invention, such as Composition 2 which is shown to reduce levels of CRP by approximately 50% and reduce levels of IL-1 gene activity by approximately 80%, is useful in modulating an inflammatory response and thereby treating cardiovascular conditions.
[00143] Additionally, it is believed that the IL-1 regulating composition of the invention may be used to limit or to control an inflammatory response due to surgery, trauma and allergic reactions involving the skin, lungs, eyes, ears, nose, throat, digestive tract, nervous system and the like.
[00144] Furthermore, it has been observed that nervous system cells and tissue secrete significant amounts of IL-1 and when stressed under inflammation, and therefore, the composition may be used to treat mental problems, headaches and earaches, as well as debilitating neurological diseases such as Alzheimer's diseases.
[00145] The above descriptions are those of the preferred embodiments of the invention. Various alterations and changes can be made without departing from the spirit and broader aspects of the invention as defined in the appended claims, which are to be interpreted in accordance with the principles of patent law including the
doctrine of equivalents. Any references to claim elements in the singular, for example, using the articles "a," "an," "the," or "said," is not to be construed as limiting the element to the singular.
Claims
1. A method of modulating an inflammatory response in a subject comprising providing a composition comprising rosehips and at least one of blackberry, blueberry, resveratrol or derivatives thereof, viniferin, and Aframomum melegueta extract, wherein administration of the composition reduces synthesis of at least one mediator of inflammation.
2. The method of claim 1 wherein the composition includes rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, and Aframomum melegueta extract.
3. The method of claim 1 , wherein the at least one mediator of inflammation is interleukin-1.
4. The method of claim 3, wherein reducing the synthesis of a mediator of inflammation further comprises blocking transcription of interleukin-1.
5. The method of claim 1 , wherein the mediator of inflammation is a C reactive protein.
6. The method of claim 3, further comprising reducing the synthesis of a second mediator of inflammation.
7. The method of claim 6, wherein the second mediator of inflammation is a C reactive protein.
8. The method of claim 1 , wherein the subject has an IL-1 Pattern 1 genotype.
9. The method of claim 1 , wherein the composition comprises 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or derivatives thereof.
10. The method of claim 2, wherein the composition comprises about 1200 mg of rosehips, about 330 mg of blackberry powder, about 165 mg of blueberry powder, and about 40 mg of resveratrol or derivatives thereof.
11. The method of claim 1 , wherein the composition comprises 800-1500 mg of rosehips, 20-150 mg of resveratrol or derivatives thereof, and 150-500 mg of Aframomum melegueta extract.
12. The method of claim 2, wherein the composition comprises about 1200 mg of rosehips, about 40 mg of resveratrol or derivatives thereof, and about 300 mg of Aframomum melegueta extract.
13. A method of modulating an inflammatory response in a subject comprising providing a composition comprising rosehips and at least one of blackberry, blueberry, resveratrol or derivatives thereof, viniferin and Aframomum melegueta extract, wherein administration of the composition reduces expression of at least one mediator of inflammation.
14. The method of claim 13 wherein the composition includes rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, and Aframomum melegueta extract.
15. The method of claim 13, wherein the at least one mediator of inflammation is interleukin-1.
16. The method of claim 13, wherein the mediator of inflammation is a C reactive protein.
17. The method of claim 13, further comprising reducing the synthesis of a second mediator of inflammation.
18. The method of claim 17, wherein the second mediator of inflammation is a C reactive protein.
19. The method of claim 13, wherein the subject has an IL-1 Pattern 1 genotype.
20. The method of claim 13, wherein reducing the expression of a mediator of inflammation further comprises reducing the levels of the interleukin-1 in the serum of the subject.
21. The method of claim 13, wherein the composition comprises 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or derivatives thereof.
22. The method of claim 13, wherein the composition comprises about 1200 mg of rosehips, about 330 mg of blackberry powder, about 165 mg of blueberry powder, and about 40 mg of resveratrol or derivatives thereof.
23. The method of claim 13, wherein the composition comprises 800-1500 mg of rosehips, 20-150 mg of resveratrol or derivatives thereof, and 150-500 mg of Aframomum melegueta extract.
24. The method of claim 13, wherein the composition comprises about 1200 mg of rosehips, about 40 mg of resveratrol or derivatives thereof, and about 300 mg of Aframomum melegueta extract.
25. The method of claim 13, wherein the composition comprises about 1200 mg of rosehips, about 330 mg of blackberry powder, about 165 mg of blueberry powder, and about 40 mg of resveratrol or derivatives thereof, and wherein the subject has an IL-1 Pattern 1 genotype.
26. The method of claim 13, wherein the composition comprises about 1200 mg of rosehips, about 40 mg of resveratrol or derivatives thereof, and about 300 mg of Aframomum melegueta extract and wherein the subject has an IL-1 pattern 1 genotype.
27. A dietary supplement for modulating an immune response in a subject comprising rosehips and at least one of blueberry, blackberry, resveratrol or derivatives thereof, viniferin, and Aframomum melegueta extract, wherein the dietary supplement is effective for reducing the synthesis of an inflammatory cytokine.
28. The dietary supplement composition of claim 27 wherein the composition includes rosehips, at least one of resveratrol and viniferin and at least one of blackberry, blueberry, and Aframomum melegueta extract.
29. The dietary supplement of claim 27, wherein the inflammatory cytokine is interleukin-1.
30. The dietary supplement of claim 27, further comprising 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or derivatives thereof.
31. The dietary supplement of claim 27, wherein the composition comprises 800- 1500 mg of rosehips, 20-150 mg of resveratrol or derivatives thereof, and 150-500 mg of Aframomum melegueta extract.
32. A dietary supplement for modulating an immune response in a subject comprising rosehips, at least one of resveratrol and viniferin, and at least one of blueberry, blackberry, and Aframomum melegueta extract, wherein the dietary supplement is effective for reducing the expression of an inflammatory cytokine.
33. The dietary supplement of claim 32, wherein the inflammatory cytokine is interleukin-1.
34. The dietary supplement of claim 32, further comprising 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or viniferin.
35. The dietary supplement of claim 32, further comprising 800-1500 mg of rosehips, 20-150 mg of resveratrol or viniferin, and 150-500 mg of Aframomum melegueta extract.
36. A method of modulating an inflammatory response in a subject comprising providing a composition comprising rosehips and at least one of blackberry, blueberry, resveratrol or derivatives thereof, viniferin, and Aframomum melegueta extract, wherein administration of the composition prevents an increase in the synthesis of at least one mediator of inflammation.
37. The method of claim 36, wherein the composition includes rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, and Aframomum melegueta extract.
38. The method of claim 36, wherein the at least one mediator of inflammation is interleukin-1.
39. The method of claim 36, wherein the mediator of inflammation is a C reactive protein.
40. The method of claim 38, further comprising reducing the synthesis of a second mediator of inflammation.
41. The method of claim 40, wherein the second mediator of inflammation is a C reactive protein.
42. The method of claim 36, wherein the subject has an IL-1 Pattern 1 genotype.
43. The method of claim 36, wherein the composition comprises 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or derivatives thereof.
44. The method of claim 37, wherein the composition comprises about 1200 mg of rosehips, about 330 mg of blackberry powder, about 165 mg of blueberry powder, and about 40 mg of resveratrol or derivatives thereof.
45. The method of claim 36, wherein the composition comprises 800-1500 mg of rosehips, 20-150 mg of resveratrol or derivatives thereof, and 150-500 mg of Aframomum melegueta extract.
46. The method of claim 37, wherein the composition comprises about 1200 mg of rosehips, about 40 mg of resveratrol, and about 300 mg of Aframomum melegueta extract.
47. A method of modulating an inflammatory response in a subject comprising providing a composition comprising rosehips and at least one of blackberry, blueberry, resveratrol or derivatives thereof, viniferin and Aframomum melegueta extract, wherein administration of the composition prevents an increase in the expression of at least one mediator of inflammation.
48. The method of claim 47, wherein the composition includes rosehips, at least one of resveratrol and viniferin, and at least one of blackberry, blueberry, and Aframomum melegueta extract.
49. The method of claim 48, wherein the at least one mediator of inflammation is interleukin-1.
50. The method of claim 47, wherein the mediator of inflammation is a C reactive protein.
51. The method of claim 49, further comprising reducing the synthesis of a second mediator of inflammation.
52. The method of claim 51 , wherein the second mediator of inflammation is a C reactive protein.
53. The method of claim 47, wherein the subject has an IL-1 Pattern 1 genotype.
54. The method of claim 47, wherein the composition comprises 800-1500 mg of rosehips, 200-500 mg of blackberry powder, 50-300 mg of blueberry powder, and 20-150 mg of resveratrol or derivatives thereof.
55. The method of claim 47, wherein the composition comprises 800-1500 mg of rosehips, 20-150 mg of resveratrol or derivatives thereof, and 150-500 mg of Aframomum melegueta extract.
56. The method of claim 47, wherein the composition comprises about 1200 mg of rosehips, about 330 mg of blackberry powder, about 165 mg of blueberry powder, and about 40 mg of resveratrol or derivatives thereof, and wherein the subject has an IL-1 Pattern 1 genotype.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008528086A JP2009506044A (en) | 2005-08-23 | 2006-08-23 | Cytokine modulators and related methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71073005P | 2005-08-23 | 2005-08-23 | |
US60/710,730 | 2005-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007024901A1 true WO2007024901A1 (en) | 2007-03-01 |
Family
ID=37575241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/032847 WO2007024901A1 (en) | 2005-08-23 | 2006-08-23 | Cytokine modulators and related methods of use |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2009506044A (en) |
KR (1) | KR20080041703A (en) |
CN (1) | CN101291681A (en) |
WO (1) | WO2007024901A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3096893A1 (en) * | 2019-06-06 | 2020-12-11 | Laboratoire Exact | COMPOSITION BASED ON YOUNG SHOOTS EXTRACT AND USE FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO AGING |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009030351A1 (en) * | 2009-06-22 | 2010-12-23 | Gelita Ag | Composition for the treatment of degenerative joint diseases |
KR101056129B1 (en) * | 2009-12-15 | 2011-08-11 | 주식회사 엘지생활건강 | Anti-inflammatory composition |
EP2433629B1 (en) * | 2010-09-22 | 2017-11-08 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Use of boswellic acids for the prophylaxis and/or treatment of damages and/or inflammation of the islets of Langerhans |
CN102258191B (en) * | 2010-12-23 | 2012-12-19 | 天津天狮生物发展有限公司 | Antioxidative health-care food for preventing chronic inflammation and preparation method thereof |
ITMI20121570A1 (en) * | 2012-09-20 | 2014-03-21 | Indena Spa | NEW EXTRACTS OF CYNARA SCOLIMUS, COFFEA SPP. AND EUROPEAN OLEA FOR THE TREATMENT OF METABOLIC SYNDROME |
KR101944113B1 (en) * | 2017-09-28 | 2019-01-30 | 동의대학교 산학협력단 | Composition for relieving and improving acute facial pain |
TWI732147B (en) * | 2018-10-26 | 2021-07-01 | 臺北醫學大學 | Extracts and compositions for inhibiting acetylcholinesterase |
CN109907144A (en) * | 2019-04-19 | 2019-06-21 | 陕西科技大学 | It is a kind of to have effects that control the blueberry nettle tea and preparation method thereof of blood glucose |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999053934A1 (en) * | 1998-04-17 | 1999-10-28 | HANSEN, Otto, Torbjørn | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
DE10153949A1 (en) * | 2000-11-07 | 2002-08-01 | Engelbert Grzeschik | Use of berry seed oil in phytopharmacy, cosmetics and foods, as source of polyunsaturated fatty acids and antioxidants |
WO2005025586A1 (en) * | 2003-09-12 | 2005-03-24 | Access Business Group International Llc | Cytokine modulators and related method of use |
WO2005027716A2 (en) * | 2003-09-12 | 2005-03-31 | Access Business Group International Llc | Program for regulating health conditions |
WO2005112965A2 (en) * | 2004-05-20 | 2005-12-01 | Rutgers, The State University Of New Jersey | Botanical anti-inflammatory compositions and methods |
-
2006
- 2006-08-23 CN CNA2006800392181A patent/CN101291681A/en active Pending
- 2006-08-23 JP JP2008528086A patent/JP2009506044A/en active Pending
- 2006-08-23 KR KR1020087006426A patent/KR20080041703A/en not_active Application Discontinuation
- 2006-08-23 WO PCT/US2006/032847 patent/WO2007024901A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999053934A1 (en) * | 1998-04-17 | 1999-10-28 | HANSEN, Otto, Torbjørn | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
DE10153949A1 (en) * | 2000-11-07 | 2002-08-01 | Engelbert Grzeschik | Use of berry seed oil in phytopharmacy, cosmetics and foods, as source of polyunsaturated fatty acids and antioxidants |
WO2005025586A1 (en) * | 2003-09-12 | 2005-03-24 | Access Business Group International Llc | Cytokine modulators and related method of use |
WO2005027716A2 (en) * | 2003-09-12 | 2005-03-31 | Access Business Group International Llc | Program for regulating health conditions |
WO2005112965A2 (en) * | 2004-05-20 | 2005-12-01 | Rutgers, The State University Of New Jersey | Botanical anti-inflammatory compositions and methods |
Non-Patent Citations (14)
Title |
---|
ANONYMOUS: "BLUEBERRY tea", INTERNET CITATION, pages 1, XP002414477, Retrieved from the Internet <URL:http://teanewengland.com/catalog/product_info.php?cPath=21&products_id=28> * |
ANONYMOUS: "Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People", INTERNET CITATION, pages 1 - 4, XP002414246, Retrieved from the Internet <URL:http://www.clinicaltrials.gov/show/NCT00303238> [retrieved on 20070110] * |
ANONYMOUS: "WILDBERRY WITH BLACKBERRY,RASBERRY & BLUEBERRY TEA", INTERNET CITATION, pages 1 - 2, XP002313012, Retrieved from the Internet <URL:http://www.healtheries.co.nz/page.php?id=25&prod=1088> * |
BARAK V ET AL: "THE EFFECT OF HERBAL REMEDIES ON THE PRODUCTION OF HUMAN INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES", IMAJ, IR, vol. 4, no. SUPPL 11, November 2002 (2002-11-01), pages 919 - 922, XP009042253, ISSN: 1565-1088 * |
CHERYL LYNN DYBAS: "Gorilla Staple Adds Spice to New Drugs", INTERNET CITATION, 21 November 2006 (2006-11-21), pages 1 - 2, XP002414242, Retrieved from the Internet <URL:http://www.washingtonpost.com/wp-dyn/content/article/2006/11/26/AR2006112600730_pf.html> [retrieved on 20070110] * |
CHINESE JOURNAL OF NATURAL MEDICINES 2004 CHINA, vol. 2, no. 3, 2004, pages 176 - 183, ISSN: 1672-3651 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2004, LIU B-L ET AL: "Vaticanol (B, C and G), [alpha]-viniferin, and hopeaphenol inhibit mediator release from bone marrow-derived mouse mast cells in vitro", XP002414243, Database accession no. EMB-2004335758 * |
DATABASE WPI Week 199417, Derwent World Patents Index; AN 1994-138101, XP002313017 * |
GAO X ET AL: "Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 62, 1 November 2001 (2001-11-01), pages 1299 - 1308, XP002197358, ISSN: 0006-2952 * |
MANNA S K ET AL: "Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, no. 12, 15 June 2000 (2000-06-15), pages 6509 - 6519, XP002313010, ISSN: 0022-1767 * |
ROSSI A ET AL: "PROTECTIVE EFFECTS OF ANTHOCYANINS FROM BLACKBERRY IN A RAT MODEL OF ACUTE LUNG INFLAMMATION", FREE RADICAL RESEARCH,, YVERDON, CH, vol. 37, no. 8, August 2003 (2003-08-01), pages 891 - 900, XP009042260, ISSN: 1071-5762 * |
UMUKORO S ET AL: "EFFECTS OF AFRAMOMUM MELEGUTA SEED EXTRACT ON THERMAL PAIN AND CARRAGEENIN - INDUCED OEDEMA", NIGERIAN QUARTERLY JOURNAL OF HOSPITAL MEDICINE, LAGOS UNIVERSITY MEDICAL SOCIETY, LAGOS, NG, vol. 11, no. 1-4, December 2001 (2001-12-01), pages 33 - 35, XP008055087, ISSN: 0189-2657 * |
YESILADA E ET AL: "INHIBITORY EFFECTS OF TURKISH FOLK REMEDIES ON INFLAMMATORY CYTOKINES: INTERLEUKIN-1ALPHA, INTERLEUKIN-1BETA AND TUMOUR NECROSIS FACTOR ALPHA", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 58, 1997, pages 59 - 73, XP000974123, ISSN: 0378-8741 * |
YOUDIM KURESH A ET AL: "Potential role of dietary flavonoids in reducing microvascular endothelium vulnerability to oxidative and inflammatory insults", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 13, no. 5, May 2002 (2002-05-01), pages 282 - 288, XP002313008, ISSN: 0955-2863 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3096893A1 (en) * | 2019-06-06 | 2020-12-11 | Laboratoire Exact | COMPOSITION BASED ON YOUNG SHOOTS EXTRACT AND USE FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO AGING |
Also Published As
Publication number | Publication date |
---|---|
JP2009506044A (en) | 2009-02-12 |
KR20080041703A (en) | 2008-05-13 |
CN101291681A (en) | 2008-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7838050B2 (en) | Cytokine modulators and related method of use | |
US7758903B2 (en) | Cytokine modulators and related methods of use | |
WO2007024901A1 (en) | Cytokine modulators and related methods of use | |
JP2007513868A5 (en) | ||
US7758902B2 (en) | Cytokine modulators and related methods of use | |
JP4514333B2 (en) | Rose berry formulation as a natural anti-inflammatory drug to alleviate and reduce symptoms associated with inflammation and arthritis | |
US5932624A (en) | Vitamin supplement composition | |
Raygan et al. | A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with coronary heart disease: a randomized, double‐blinded, placebo‐controlled trial | |
JP2013136587A (en) | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type1 and type 2 cytokine production | |
KR20090036579A (en) | Novel agents for the treatment of disorders connected to impaired neurotransmission | |
JP7011885B2 (en) | Composition that promotes intestinal health | |
CN101437503A (en) | Compositions to reduce blood glucose levels and treat diabetes | |
CA2403271A1 (en) | Maca and antler for augmenting testosterone levels | |
US20140148399A1 (en) | Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia | |
US20190160138A1 (en) | Dietary supplement for gluten reaction | |
US5846544A (en) | Composition and method for reducing blood sugar levels in diabetic humans | |
JP2003327528A (en) | Immunocompetence-improving composition | |
WO2023074708A1 (en) | Food product for improving sleep onset | |
Bagchi et al. | Phytoceutical-based Traditional Weight Loss Strategies for Management of Body Recomposition: Common Misconceptions and Novel Technological Breakthroughs | |
Kurpad et al. | The effect of Ivy Gourd (Coccinia cordifolia) extract on diabetic patients | |
US20230030835A1 (en) | Polyphenol compositions and uses thereof | |
Fadimatou et al. | In vitro antidiabetic potential of two formulated powders of some nutraceutical plants of Cameroon | |
RU2238749C2 (en) | Method for prophylaxis and treatment of pathology caused by elevated and/or reduced content of physiologically necessary macroelements and trace elements in human body | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680039218.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008528086 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087006426 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06802126 Country of ref document: EP Kind code of ref document: A1 |